



World Scleroderma
Foundation

VIRTUAL CONGRESS

7TH
SYSTEMIC
SCLEROSIS
WORLD
CONGRESS

MARCH **10-12**, 2022

www.worldsclerofound.org

TABLE OF CONTENTS

COMMITTEES pag. 4

CONGRESS FORMAT pag. 5

PRE-CONGRESS COURSES AND PRIMERS pag. 6

PRE-RECORDED LECTURES AND ORAL PRESENTATIONS pag. 9

LIVE PROGRAMME AT A GLANCE pag. 16

LIVE PROGRAMME pag. 18

LIVE SATELLITE SYMPOSIA pag. 35

POSTER SESSION pag. 37

PATRONAGE pag. 49

ACKNOWLEDGEMENT pag. 50

Boehringer Ingelheim kindly invites you to a satellite symposium:

From research to individual patient care: clinical decision-making in SSc-ILD

When: Thursday March 10, 2022; 13:30–15:00 CET

This symposium will take place live between 13:30–15:00 CET on Thursday March 10, 2022. Presentations will be available on demand from March 10, 2022.

Please join us to hear insights from a faculty of multidisciplinary experts exploring evidence-based approaches to identifying, monitoring and managing interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Featuring presentations that examine patient case studies, you will have the opportunity to have your questions answered in a live, interactive panel discussion.

Agenda

Chairs: Christopher Denton and Oliver Distler

Time (CET)	Session	Speaker/Moderator
13:30 – 13:35	Welcome and introduction	Oliver Distler
13:35 – 14:15	Multidisciplinary discussion of SSc-ILD: from research to individual patient care	Oliver Distler, Anna-Maria Hoffmann-Vold & Toby Maher
14:15 – 14:35	Clinical decision making in SSc-ILD: what has changed?	Christopher Denton & Vanessa Smith
14:35 – 14:55	Panel discussion	All, moderated by Christopher Denton
14:55 – 15:00	Close	Oliver Distler

Medical Education with Boehringer Ingelheim

COMMITTEES

HONORARY PRESIDENTS

C Black, A Tyndall, T Medsger F Wollheim, K Takehara

STEERING COMMITTEE

DE Furst, T Krieg, M Matucci-Cerinic, O Distler, Y Allanore, M, Kuwana, D Khanna, J Seibold, C Denton

EULAR Liaison: U Mueller-Ladner

Chairs of Mentoring Programme: L Czirjak

Fesca President: S Farrington

SCIENTIFIC COMMITTEE

D Abraham (UK)
J Avouac (F)
A Balbir-Gurmann (Isr)
M Baron (Can)
S Bellando Randone (I)
L Beretta (I)
S Bosello (I)
C Bruni (I, CH)
P Carreira (E)
I Castellvi (E)
L Chung (USA)
M Cutolo (I)
L Dagna (I)
N Damjanov (Sr)
JJK De Vries-Bouwstra (NI)
J Distler (D)
I Foeldvari (D)
Chingching Foochareon (Thai)
T Frech (USA)
A Gabrielli (I)
D Giuggioli (I)
S Guiducci (I)
E Hachulla (F)
A Herrick (UK)
M Hinchcliff (USA)
M Hughes (UK)
A Hoffmann-Vold (N)
L Hummers (USA)

N Hunzelmann (D)
M Inanc (Tr)
S Johnson (CAN)
JB Jun (Korea)
S Kafaja (USA)
B Kahaleh (USA)
C Kayser (Br)
Y Kawaguchi (Jp)
O Kowal-Bielecka (Pl)
R Lafyatis (USA)
D Launay (F)
A Lescoat (F)
EB Lee (Korea)
Y Levy (Isr)
MT Li (China)
T Matsushita (Jp)
B Maurer (CH)
Z McMahan (USA)
C Mihai (Ro)
P Moinzadeh (D)
L Mouthon (F)
V Nagaraja (USA)
M Nikpour (AU)
J Pauling (UK)
J Pope (CAN)
S Proudman (AU)
G Riemekasten (D)
P Sampaio Barros (Br)

R Silver (USA)
V Smith (B)
K Solanki (New Zealand)
V Steen (USA)
Y Suliman (Egypt)
M Tikly (South Africa)
ME Truchetet (F)
J van Laar (NI)
J Varga (USA)
E Volkmann (USA)
M Vonk (NI)
U Walker (CH)
J Wang (China)
Y Wang (China)
X Zeng (China)

CO-CHAIRS OF THE SCIENTIFIC PROGRAMME COMMITTEE

Clinical: S Proudman, M Mayes

Basic: F Del Galdo, S Assassi

CO-CHAIRS OF THE ABSTRACT COMMITTEE

M Hinchcliff

H Yasuoka

CONGRESS FORMAT

CONGRESS SESSIONS

All lectures and oral communications will be pre-recorded and published on the platform in the PRE-RECORDED PRESENTATIONS section for participant's viewing **from March 1, 2022**.

During the 3 days of the live congress (March 10,11 and 12) the pre-recorded presentations will be only discussed in specific "Discussion Sessions". These will be repeated twice in the same day to cover all worldwide time zones.

Pharma Satellite Symposia will run live.

All live congress sessions will be recorded and will remain at disposal on demand to all registered participants **until September 12, 2022**, together with the pre-recorded presentations. **Live programme will run on Central European Time (CET).**

PRE-CONGRESS COURSES

Pre-Congress Courses and Primers will be organized on **Wednesday March 9** as indicated in the programme, only for participants previously registered. Attendees will receive the access link by email few days earlier.

SATELLITE SYMPOSIA

Satellite Symposia will run live during the congress days as indicated in the live programme.

3 LIVE CONGRESS DAYS - MARCH 10, 11 AND 12

Live Congress programme will run on Central European Time (CET).

During the three live congress days, presentations will only be discussed in the Live Discussion Sessions with the available speakers, according to the live programme. During the viewing, participants may submit written questions which will be evaluated by the speaker and moderators and possibly discussed during the live Discussion Sessions.

Questions will be possible **until Monday 7 March, 2022 at 18:00 CET**.

Discussion sessions will be repeated twice in the same day.

The live congress days will be recorded and available in the "ON DEMAND" section **until September 12 2022**.

POSTER PRESENTATIONS

Posters will be charged into the platform and will be at disposal for all participants. Authors will upload the pdf file of the poster and a 3-minutes recording speech.

Authors can activate their email address where participants can contact them.

PRE-CONGRESS COURSES AND PRIMERS

Pre-congress Courses and Primers will be organized as webinar on **Wednesday, March 9, 2022** at the indicated time. The link to connect to the webinar will be sent by email to the reserved participants few days **before March 9**.

PRE-CONGRESS COURSES

CAPILLAROSCOPY FROM 13:30 TO 15:00 CET

13:30-13:35

Welcome and introduction

A Herrick (UK)

13:35-13:45

The significance of nailfold capillaroscopy in patients with Systemic Sclerosis (SSc) or suspected SSc

M Cutolo (Italy)

13:45-14:00

Assessing nailfold capillary abnormalities: normal versus pathological

V Smith (Belgium)

14:00-14:10

Different capillaroscopic methods

F Ingegnoli (Italy)

14:10-14:40

Video demonstrations

14:40-14:50

Case studies

A Herrick (UK)

15:50-15:00

Future research applications

A Murray (UK)

ILD FROM 14:00 TO 15:30 CET

14:00-14:05

Presentation of the Course

K Highland (USA)

14:05-14:30

Pathobiology of scleroderma associated interstitial lung disease

O Distler (CH)

14:30-14:55

Epidemiology, diagnosis and prognosis of scleroderma associated interstitial lung disease

E Volkman (USA)

14:55-15:20

Treatment of scleroderma associated interstitial lung disease

K Highland (USA)

15:20-15:30

Discussion

DIGITAL ULCERS IN SSC FROM 13:30 TO 15:00 CET

A COMPREHENSIVE APPROACH TO THE ASSESSMENT AND MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS

13:30-13:35

Introduction and objectives

M Hughes (UK)

13:35-13:45

Clinical overview and burden of digital ulcers

M Matucci-Cerinic (Italy)

13:45-14:00

Clinical Assessment of DUs.

Definition, categorisation, and classification

C Bruni (Italy)

14:00-14:10

Local assessment and management of DUs

B Alcacer-Pitarch (UK)

14:10-14:20

Video of debridement

K El Aoufy (Italy)

14:20-14:35

Pharmacological management of DUs

D Giuggioli (Italy)

14:35-14:45

Current challenges and future perspectives

M Hughes (UK)

14:45-15:00

Questions and answers

All faculty

15:00

Summary and closing remarks

M Hughes (UK)

PRE-CONGRESS PRIMERS

CLINICAL EXAMINATION OF SSC PATIENTS FROM 13:30 TO 15:00 CET

13:30

Introduction

E Hachulla (France)

13:35-14:05

Cardiopulmonary examination

E Hachulla (France)

14:05-14:35

Extra cardiopulmonary examination

P Clements & S Kafaja (USA)

14:35-15:00

Discussion

PRIMER ON SYSTEMIC SCLEROSIS FROM 13:00 TO 15:30 CET

13:00-13:30

ILD and arthritis in SSc

J Pope (Canada)

13:30-14:00

Vasculopathy and Myocardial involvement in SSc

M Matucci-Cerinic (Italy)

14:00-14:30

Discussion

14:30-15:00

Pathogenesis - Updates

J Varga (USA)

15:00-15:30

Discussion

Management of connective tissue disease-associated pulmonary arterial hypertension: A multidisciplinary approach

Friday, 11
March 2022

Janssen
Satellite
Symposium

13:30–15:00
(CET)

CO-CHAIRS

Sean Gaine
Pulmonologist
Mater Misericordiae University
Hospital, Dublin, Ireland

Anna-Maria Hoffmann-Vold
Rheumatologist
Oslo University Hospital,
Oslo, Norway

FACULTY

Oliver Distler
Rheumatologist
University Hospital Zurich,
Zurich, Switzerland

Serena Guiducci
Rheumatologist
University of Florence,
Florence, Italy

Jean-Luc Vachiéry
Cardiologist
Erasmus University
Hospital, Brussels, Belgium

LEARNING OBJECTIVES

1. Describe the importance of screening systemic sclerosis (SSc) patients for associated complications, such as pulmonary arterial hypertension (PAH), to allow for early intervention
2. Address the importance of multidisciplinary teams and the role of communication and knowledge exchange for early diagnosis of SSc-PAH
3. Discuss treatment strategies for patients with SSc-PAH, with a focus on clinical practice within a multidisciplinary team

AGENDA

Time	Title	Speaker(s)
13:30–13:35	Welcome and introduction	Anna-Maria Hoffmann-Vold
13:35–13:55	Pearls and pitfalls: Screening and diagnosis of PAH in SSc patients	Serena Guiducci
13:55–14:35	Roundtable discussion: The importance of timely treatment and a multidisciplinary approach for SSc-PAH patients	Sean Gaine Anna-Maria Hoffmann-Vold Oliver Distler Jean-Luc Vachiéry
14:35–14:50	Q&A: Panel discussion and audience questions	All Moderated by Sean Gaine and Anna-Maria Hoffmann-Vold
14:50–15:00	Key messages and closing remarks	Sean Gaine

PRE-RECORDED LECTURES AND ORAL PRESENTATIONS

The following presentations of the congress sessions will not run during the live congress days, they will be pre-recorded and will be available in the "PRE-RECORDED PRESENTATIONS" on the Congress platform for participants' viewing starting **from March 1, 2022**. Satellite Symposia will run live.

During the viewing, participants may submit written questions which will be evaluated by the Chairperson and possibly discussed during the live Discussion Sessions.

Questions will be possible **until Monday 7 March, 2022 at 18:00 CET**.

Questions for lectures whose speakers will not attend the live Discussion Sessions will not be possible.

Opening Lectures and Sessions 17 will only be recorded and not discussed, therefore questions will not be possible.

During the 3 live congress days (March 10,11 and 12) the pre-recorded presentations will be discussed in specific "Discussion Sessions". These will be repeated twice on the same day, with the speakers available, to cover worldwide all time zones.

See the programme of the [live congress days](#).

**AVAILABLE IN THE PLATFORM
FROM MARCH 1, 2022**

OPENING LECTURE BASIC
S Assassi (USA)

No live discussion

OPENING LECTURE CLINICAL
Y Allanore (France)

No live discussion

SESSION 1 - ILD

Pathophysiology of ILD
M Kolb (Canada)

Insights and recent concepts from IPF translated to SSc ILD
V Cottin (France)

Changing landscape for treatment SSc ILD
E Volkman (USA)

OC 1 - CAN DUAL-ENERGY CT LUNG PERFUSION DETECT ABNORMALITIES AT THE LEVEL OF LUNG CIRCULATION IN SYSTEMIC SCLEROSIS (SSC)? PRELIMINARY EXPERIENCE IN 101 PATIENTS
V. Koether (France)

OC 2 - A HISTOGRAM-BASED DENSITOMETRY INDEX TO IDENTIFY AND ASSESS THE SEVERITY OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: APPLICABILITY IN STANDARD AND LOW-DOSE COMPUTED TOMOGRAPHY
C Bruni (Italy)

OC 3 - INCREASED EXPRESSION AND PROFIBROTIC EFFECTS OF LIM AND CYSTEINE-RICH DOMAINS-1 PROTEIN IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE
G Bogatkevich (USA)

Discussion at live congress:
Thursday, March 10 - [10:00-10:30](#) & [17:00-17:30](#)

SESSION 2 - HEART INVOLVEMENT

Cardiac involvement in SSc versus other Autoimmune diseases
S Plein (UK)

Definition of pHiSSc
C Bruni (Italy)

OC 4 - SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETA2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPONIN T AND MAY HELP TO IDENTIFY PATIENTS WITH CLINICAL PROGRESS IN SSC
L Schumacher (Germany)

OC 5 - CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS MYOCARDITIS: THE VALUE OF T2 MAPPING TO DETECT MYOCARDIAL INFLAMMATION
G De Luca (Italy)

OC 6 - CHANGES IN MICROCIRCULATION ASSESSED BY NAIFOLD VIDEOCAPILLAROSCOPY IN SYSTEMIC SCLEROSIS PATIENTS TREATED BY BIOLOGICS
E Bertoldo (Italy)

OC 7 - FAPI-PET/CT FOR THE ASSESSMENT OF SYSTEMIC SCLEROSIS-RELATED MYOCARDIAL FIBROSIS
C Bergmann (Germany)

Discussion at live congress:
Thursday, March 10 - [10:30-11:00](#) & [15:00-15:30](#)

SESSION 3 - PULMONARY ARTERIAL HYPERTENSION

From pathophysiology to novel therapeutic targets for PAH
M Humbert (France)

Advances in the management including the treatment of SSc PAH
V McLaughlin (USA)

OC 8 - NAIFOLD CAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS- ASSOCIATED PULMONARY HYPERTENSION; PROFILING OF NON-INVASIVE MARKERS, A COHORT STUDY
J Lemmers (The Netherlands)

OC 9 - PULMONARY VASCULAR VOLUME ON HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN THE PREDICTION OF PRE-CAPILLARY PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS
C Bruni (Italy)

OC 10 - SERUM LEVELS OF THE SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS ARE PROSPECTIVELY ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS
IM Atzeni (The Netherlands)

Discussion at live congress:
Thursday, March 10 - [12:30-13:00](#) & [17:30-18:00](#)

SESSION 4 - VASCULAR

Unmet need in the management of peripheral vascular complications
J Pauling (UK) & T Frech (USA)

OC 11 - G- CSF TREATMENT FOR REFRACTORY DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
D Rimar (Israel)

OC 12 - CHORIORETINAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS
PG Cerasuolo (Italy)

OC 13 - PREDICTION OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS BASED ON THE USE OF PLATELET INHIBITORS AND OTHER PARAMETERS - A EUSTAR STUDY ON DERIVATION AND VALIDATION OF A PREDICTION MODEL
A Garaiman (Switzerland)

OC 14 - RELEASE OF HIGH-MOBILITY GROUP BOX-1 AFTER A RAYNAUD'S ATTACK POTENTIALLY LEADS TO FIBROBLAST ACTIVATION AND INTERFERON GAMMA-INDUCED PROTEIN-10 PRODUCTION IN SYSTEMIC SCLEROSIS
IM Atzeni (The Netherlands)

Discussion at live congress:
Thursday, March 10 - [11:00-11:30](#) & [16:00-16:30](#)

SESSION 5 - DEBATE ON KIDNEY INVOLVEMENT

Renal disease - challenges and recent progress

C Denton (UK)

Recent advances in renal transplantation in SSc: data from the EU register

A D Salama (UK)

Discussion at live congress:

Thursday, March 10 - [12:00-12:30](#) & [16:30-17:00](#)

SESSION 6 EARLY CLINICAL TRIALS & OUTCOME MEASURES

White paper

P Merkel (USA) & D Khanna (USA)

OC 15 - SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI): ASSESSMENT OF PROGRESSION IN A SINGLE CENTER COHORT
Y Yancilkaya (Turkey)

OC 16 - MOBILIZATION WITH REDUCED CYCLOPHOSPHAMIDE DOSE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
AC Pecher (Germany)

OC 17 - DOMAINS AND OUTCOME MEASURES FOR THE ASSESSMENT OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: AN INTERNATIONAL COLLABORATIVE SCOPING REVIEW
A Lescoat (France)

OC 18 - CLINICAL WORSENING FOLLOWING TAPERING OR WITHDRAWAL OF TOCILIZUMAB IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A REAL-WORLD EXPERIENCE
Y Isomura (Japan)

OC 19 - PREDICTORS OF MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS
E Dourado (Portugal)

Discussion at live congress:

Thursday, March 10 - [13:00-13:30](#) & [15:30-16:00](#)

SESSION 7 - THERAPY IN SSC

Evolution of therapies in SSc, from the first treatment to the present reality

J Seibold (USA)

OC 20 - NINTE DANIB (NTD) REAL-LIFE EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC)-INTERSTITIAL LUNG DISEASE (ILD): AN ITALIAN MULTICENTRE PRELIMINARY STUDY
C Campochiaro (Italy)

OC 21 - RISK STRATIFICATION AND TREATMENT REGIMENS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
HJ Bjørkekjær (Norway)

OC 22 - EFFECTS OF NINTE DANIB IN SUBJECTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (LCSSC) AND INTERSTITIAL LUNG DISEASE (ILD): DATA FROM THE SENSIS TRIAL
Y Allanore (France)

OC 23 - EFFECT OF AN 8-WEEK PHYSICAL THERAPY PROGRAM ON SEXUAL FUNCTION IN WOMEN WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY
B Hermankova (Czech republic)

OC 24 - IMPROVEMENT IN SKIN AND PULMONARY FUNCTION TESTS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS TREATED WITH BRENTUXIMAB VEDOTIN; INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL
A Fernandez-Codina (Canada)

Discussion at live congress:

Friday, March 11 - [13:00-13:30](#) & [17:00-17:30](#)

SESSION 8 - MESENCHYMAL BASIC SCIENCE

Fibroblast Dysfunction in SSc

J Distler (Germany)

OC 25 - EVOLUTION OF SKIN INFLAMMATORY AND FIBROTIC PARAMETERS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS
A Collet (France)

OC 26 - TGF-BETA/WNT3A DEPENDENT TRANSCRIPTION OF THE HEDGEHOG TRANSCRIPTION FACTORS INITIATES THE EXPRESSION OF THE CHLORIDE INTRACELLULAR CHANNEL 4 (CLIC4) IN SSC FIBROBLASTS
C Wasson (UK)

OC 27 - ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING

A-E Györfi (Germany)

OC 28 - IMPAIRED TFAM EXPRESSION PROMOTES MITOCHONDRIAL DAMAGE TO DRIVE FIBROBLAST ACTIVATION AND FIBROSIS IN SYSTEMIC SCLEROSIS

X Zhou (Germany)

Discussion at live congress:

Friday, March 11 - [10:00-10:30](#) & [17:30-18:00](#)

SESSION 9 THE IMMUNE SYSTEM IN SYSTEMIC SCLEROSIS

Innate Immunity in Autoimmune Diseases

M Kaplan (USA)

B Cells in SSc

L Sakkas (Greece)

OC 29 - IL-2-RELATED REGULATORY CD4 T-CELL DEFICIENCY LEADS TO THE DEVELOPMENT OF LUNG FIBROSIS AND VASCULAR REMODELING

C Frantz (France)

OC 30 - AUTOANTIBODIES FROM SYSTEMIC SCLEROSIS PATIENTS TARGETING THE ANGIOTENSIN II TYPE 1 AND ENDOTHELIN-1 TYPE A RECEPTOR INDUCE ENDOTHELIAL CELL ACTIVATION AND PRO-FIBROTIC RESPONSES

C Fehres (The Netherlands)

OC 31 - HUMORAL RESPONSE TO BNT162B2 MRNA VACCINE AGAINST SARS COV2, IN SYSTEMIC SCLEROSIS PATIENTS AND THE IMPACT ON THE RHEUMATIC DISEASE ACTIVITY

A Balbir-Gurman (Israel)

Discussion at live congress:

Saturday, March 12 - [13:00-13:30](#) & [16:30-17:00](#)

SESSION 10 VASCULOPATHY AND CIRCULATING BIOMARKERS

Molecular Basis of Vasculopathy in PAH

A Olschewski (Austria)

Endothelial Cell Dysfunction in the Pathogenesis of SSc

Y Asano (Japan)

OC 32 - PHENOTYPE OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS HAVING POSITIVE ANTI-TOPOISOMERASE ANTIBODIES: DATA FROM EUSTAR COHORT

E Zanatta (Italy)

OC 33 - SERUM IFN SCORE PREDICTS LONG TERM OUTCOME IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS

R Karanth U (UK)

OC 34 - SERUM PROTEIN INTERFERON SCORE IS BIOMARKER OF ACTIVE DISEASE IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS ENROLLED IN PROSPECTIVE REGISTRY OF EARLY SYSTEMIC SCLEROSIS (PRESS) COHORT

M Hinchcliff (USA)

Discussion at live congress:

Friday, March 11 - [10:30-11:00](#) & [15:00-15:30](#)

SESSION 11 - FRONTIERS IN SCIENCE

Single Cell Gene Expression Profiling in SSc

R Lafyatis (USA)

Single-cell and spatial-seq integration in scleroderma - novel insights

J Gudjonsson (USA)

OC 35 - CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSC: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION

F Del Galdo (UK)

OC 36 - ESTABLISHMENT AND CHARACTERIZATION OF 3D LUNG ORGANOIDs GENERATED FROM A MURINE MODEL OF SYSTEMIC SCLEROSIS

V. Koether (France)

OC 37 - PATHWAY ANALYSIS FROM WHOLE BLOOD TRANSCRIPTOME REVEALS UNIQUE CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS AT THE PRECLINICAL STAGE

C Bellocchi (Italy)

OC 38 - PERIPHERAL BLOOD GENE EXPRESSION PROFILING PREDICTS RESPONSE TO MYCOPHENOLATE IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE

S Assassi (USA)

Discussion at live congress:

Saturday, March 12 - [13:30-14:00](#) & [17:00-17:30](#)

SESSION 12 - BEST FROM JOURNALS

A&R JOURNAL

Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease

D Roofeh (USA)

NATURE

Detection of microvascular changes in Systemic Sclerosis and other rheumatic diseases

M Cutolo (Italy)

RHEUMATOLOGY

Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort

M Hughes (UK)

JSRD

Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth

M Larché (Canada)

LANCET RHEUMATOLOGY

Progression to Systemic Sclerosis in patients with Raynaud's: stratified risk models for clinical management and prevention trials

F Del Galdo (UK)

Discussion at live congress:

Friday, March 11 - [12:00-12:30](#) & [16:30-17:00](#)

SESSION 13 - GI

Gastrointestinal involvement in SSc: State-of-the art and recent knowledge about disease pathogenesis

U Mueller-Ladner (Germany)

Overview on the recent clinical trial and studies in GI SSc

Z McMahan (USA)

OC 39 - USE AND PERCEPTIONS OF NUTRITION INFORMATION RESOURCES AMONG PEOPLE WITH SYSTEMIC SCLEROSIS FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT

N Østbø (Canada)

OC 40 - PREVALENCE OF GASTROINTESTINAL MANIFESTATIONS IN AN AUSTRALIAN SCLERODERMA COHORT

A Quinlivan (Australia)

OC 41 - THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI) IN A SYSTEMIC SCLEROSIS COHORT WITH 10-YEARS FOLLOW-UP

MG Lazzaroni (Italy)

Discussion at live congress:

Saturday, March 12 - [10:30-11:00](#) & [15:30-16:00](#)

SESSION 14 - COMPREHENSIVE CARE OF THE PATIENT WITH SSC IN THE WORLD

Consensus Best Practice Pathways for SSc treatment

M Buch (USA)

Diffuse Skin disease versus limited skin involvement - treatment options and management strategies in Australia

S Proudman (Australia)

SSc-ILD monitoring in the U.S.

M Mayes (USA)

Discussion at live congress:

Friday, March 11 - [12:30-13:00](#) & [16:00-16:30](#)

SESSION 15 SYSTEMIC SCLEROSIS, PREGNANCY AND SEXUAL HEALTH

Outcomes in SSc pregnancies
E Tombetti (Italy)

Challenges of diagnosing Scleroderma renal crisis in Scleroderma pregnancies
V Steen (USA)

OC 42 - THE IMPACT OF SYSTEMIC SCLEROSIS ON WOMEN HEALTH: CREATION AND ADMINISTRATION OF A NEW SSC-SPECIFIC PATIENT-REPORTED QUESTIONNAIRE
MG Lazzaroni (Italy)

OC 43 - SEXUAL FUNCTION IN MEN WITH SYSTEMIC SCLEROSIS
B Hermankova (Czech Republic)

Discussion at live congress:
Saturday, March 12 - [11:00-11:30](#) & [16:00-16:30](#)

SESSION 16 - COVID AND SSC

After the COVID storm: Vaccinations in SSc
Y Braun-Moscovici (Israel)

Is the new variant changing anything in this pandemic?
K Winthrop (USA)

OC 44 - RISK ASSESSMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASES DURING COVID-19 PANDEMIC: IS DISTANCE ASSESSMENT POSSIBLE?
A Volkov (Russia)

OC 45 - IMMUNOGENICITY OF A SINGLE DOSE OF COVID-19 VACCINATION IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH OR WITHOUT IMMUNOSUPPRESSION
V Kakkar (UK)

OC 46 - PROSPECTIVE CONTROLLED TRIAL OF IMMUNOGENICITY AND SAFETY OF AN INACTIVATED VIRUS VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC SCLEROSIS
P Sampaio Barros (Brazil)

OC 47 - THE CHARACTERISTICS OF GROUND GLASS OPACIFICATION AT COMPUTED TOMOGRAPHY MAY ALLOW A DIFFERENTIAL DIAGNOSIS BETWEEN INTERSTITIAL LUNG DISEASE BETWEEN COVID-19 AND SYSTEMIC SCLEROSIS
M Orlandi (Italy)

OC 48 - THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS REGISTERED IN THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR)
A Hoffmann-Vold (Norway)

Discussion at live congress:
Saturday, March 12 - [11:30-12:00](#) & [15:00-15:30](#)

SESSION 17 WORLDVIEW OF SSC RAYNAUD PHENOMENON TREATMENT Sharing experiences across the world

- Canadian Experience - **S Johnson (Canada)**
- US Experience - **T Frech (USA)**
- UK Experience - **J Pauling (UK)**
- Mexican experience - **T Rodriguez (Mexico)**
- South American Experience - **C Kayser (South America)**
- South Korean experience - **E B Lee (South Korea)**
- Australian Experience - **M Nikpour (Australia)**

No live discussion

SESSION 18 - FREE CLINICAL ORAL COMMUNICATIONS

OC 49 - PREDICTIVE VALUE OF ULTRASOUND PARAMETERS OF THE HAND ON THE ONSET OF CLINICAL MANIFESTATIONS DURING LONGITUDINAL FOLLOW-UP IN PATIENTS WITH SYSTEMIC SCLEROSIS
L Thibaut (France)

OC 50 - ALTERATIONS OF LIPID PROFILE IN SCLERODERMA PATIENTS AND THE ASSOCIATIONS WITH DISEASE-SPECIFIC FEATURES
S Oreska (Czech Republic)

OC 51 - SCLERODERMA IN INDIVIDUALS WITH EXPOSURE TO WORLD TRADE CENTER GROUND-ZERO AND/OR RESCUE/RECOVERY EFFORTS: A CASE SERIES
M Own (USA)

OC 52 - RAYNAUD'S PHENOMENON: EPIDEMIOLOGICAL, CLINICAL, DERMOSCOPIC, ETIOLOGICAL ASPECTS AND THERAPEUTIC MANAGEMENT IN LIVING BLACK SKIN PATIENTS IN TROPICAL AREAS
F Ly (Senegal)

OC 53 - DIGITAL GANGRENE IN CHINESE SYSTEMIC SCLEROSIS PATIENTS: A RETROSPECTIVE CASE-CONTROL STUDY
M Hui (China)

OC 54 - IMPROVEMENT WITH TIME OF VASCULAR OUTCOMES IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY

M Hughes (UK)

OC 55 - PREDICTORS OF HOSPITALIZATION IN PATIENTS WITH SYSTEMIC SCLEROSIS: A 12-YEAR COHORT STUDY OF 170 PATIENTS FROM A TERTIARY CENTER

H Assunção (Portugal)

Discussion at live congress:

Saturday, March 12 - [12:30-13:00](#) & [14:30-15:00](#)

SESSION 19 - FREE BASIC ORAL COMMUNICATIONS

OC 56 - SILDENAFIL IMPROVES THE REDOX HOMEOSTASIS AND PRO-INFLAMMATORY ACTIVATION IN SYSTEMIC SCLEROSIS FIBROBLASTS EXPOSED TO REACTIVE OXYGEN SPECIES

C Antinozzi (Italy)

OC 57 - A SELECTIVE TGF-B1 AND TGF-B3 TRAP DEMONSTRATES TARGET ENGAGEMENT AND ANTI-FIBROTIC EFFICACY IN MOUSE AND TRANSLATIONAL MODELS OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

T Barr (UK)

OC 58 - TREATMENT WITH ANTI-S100A4 MONOCLONAL ANTIBODIES AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NONINFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS

M Tomcik (Czech Republic)

OC 59 - EVALUATING NOVEL THERAPEUTIC PEPTIDE RP832C TARGETING CD206 IN MODELS OF SCLERODERMA MACROPHAGE-DEPENDENT FIBROSIS AND INFLAMMATION

R Stratton (UK)

OC 60 - IMPAIRED DIGESTION OF CIRCULATING GENOMIC DNA IN SYSTEMIC SCLEROSIS PATIENTS AND HEALTHY CONTROLS WITH THE DNASE1L3 R206C VARIANT

B Skaug (USA)

OC 61 - ANTIGEN-SPECIFIC, AUTO-REACTIVE B CELL RESPONSES REVEAL DIFFERENTIAL IMMUNOLOGICAL ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS

HU Scherer (The Netherlands)

OC 62 - SUPERB MICROVASCULAR IMAGING AS A NOVEL IMAGING TOOL FOR THE QUANTIFICATION OF FINGER TIP BLOOD FLOW IN SYSTEMIC SCLEROSIS

P Korsten (Germany)

Discussion at live congress:

Friday, March 11 - [11:00-11:30](#) & [15:30-16:00](#)

SESSION 20 - WRAP UP OF THE CONGRESS

M Kuwana (Japan) & O Distler (Switzerland)

LIVE PROGRAMME AT A GLANCE CET (Central European Time)

During the three live congress days, the congress lectures and oral communications will only be discussed in the Live Discussion Sessions with the available speakers, as indicated in the following programme. Live chat questions will be possible during live discussions. Discussion sessions will be repeated twice on the same day. Live Congress programme will run on Central European Time (CET). The live congress days will be recorded and available in the "ON DEMAND" section **until September 12, 2022.**

THURSDAY, MARCH 10

09:15-10:00	OPENING
10:00-10:30	Discussion Session 1 - ILD
10:30-11:00	Discussion Session 2 - HEART INVOLVEMENT
11:00-11:30	Discussion Session 4 - VASCULAR
11:30-12:00	BREAK
12:00-12:30	Discussion Session 5 - DEBATE ON KIDNEY INVOLVEMENT
12:30-13:00	Discussion Session 3 - PULMONARY ARTERIAL HYPERTENSION
13:00-13:30	Discussion Session 6 EARLY CLINICAL TRIALS & OUTCOME MEASURES
13:30-15:00	BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM
15:00-15:30	Discussion Session 2 - HEART INVOLVEMENT
15:30-16:00	Discussion Session 6 EARLY CLINICAL TRIALS & OUTCOME MEASURES
16:00-16:30	Discussion Session 4 - VASCULAR
16:30-17:00	Discussion Session 5 - DEBATE ON KIDNEY INVOLVEMENT
17:00-17:30	Discussion Session 1 - ILD
17:30-18:00	Discussion Session 3 - PULMONARY ARTERIAL HYPERTENSION


SATURDAY, MARCH 12

10:30-11:00	Discussion Session 13 - GI
11:00-11:30	Discussion Session 15 - SYSTEMIC SCLEROSIS, PREGNANCY AND SEXUAL HEALTH
11:30-12:00	Discussion Session 16 - COVID AND SSC
12:00-12:30	BREAK
12:30-13:00	Discussion Session 18 FREE CLINICAL ORAL COMMUNICATIONS
13:00-13:30	Discussion Session 9 THE IMMUNE SYSTEM IN SYSTEMIC SCLEROSIS
13:30-14:00	Discussion Session 11 - FRONTIERS IN SCIENCE
14:00-14:30	TALARIS THERAPEUTICS SATELLITE SYMPOSIUM

FRIDAY, MARCH 11

10:00-10:30	Discussion Session 8 - MESENCHYMAL BASIC SCIENCE
10:30-11:00	Discussion Session 10 - VASCULOPATHY AND CIRCULATING BIOMARKER
11:00-11:30	Discussion Session 19 - FREE BASIC ORAL COMMUNICATIONS
11:30-12:00	BREAK
12:00-12:30	Discussion Session 12 - BEST FROM JOURNALS
12:30-13:00	Discussion Session 14 - COMPREHENSIVE CARE OF THE PATIENT WITH SSC IN THE WORLD
13:00-13:30	Discussion Session 7 - THERAPY IN SSC
13:30-15:00	JANSSEN SATELLITE SYMPOSIUM
15:00-15:30	Discussion Session 10 VASCULOPATHY AND CIRCULATING BIOMARKERS
15:30-16:00	Discussion Session 19 - FREE BASIC ORAL COMMUNICATIONS
16:00-16:30	Discussion Session 14 - COMPREHENSIVE CARE OF THE PATIENT WITH SSC IN THE WORLD
16:30-17:00	Discussion Session 12 - BEST FROM JOURNALS
17:00-17:30	Discussion Session 7 - THERAPY IN SSC
17:30-18:00	Discussion Session 8 - MESENCHYMAL BASIC SCIENCE
18:00-18:30	MALLINCKRODT PHARMACEUTICALS SATELLITE SYMPOSIUM

14:30-15:00	Discussion Session 18 FREE CLINICAL ORAL COMMUNICATIONS
15:00-15:30	Discussion Session 16 - COVID AND SSC
15:30-16:00	Discussion Session 13 - GI
16:00-16:30	Discussion Session 15 - SYSTEMIC SCLEROSIS, PREGNANCY AND SEXUAL HEALTH
16:30-17:00	Discussion Session 9 THE IMMUNE SYSTEM IN SYSTEMIC SCLEROSIS
17:00-17:30	Discussion Session 11 - FRONTIERS IN SCIENCE
17:30-18:00	WRAP UP
18:00-18:15	CLOSING



PAH IS A SEVERE AND OFTEN FATAL COMPLICATION OF CTD¹ THAT IS ESTIMATED TO AFFECT 1 IN 10 PATIENTS WITH SSc²

Find out more about PAH at the Janssen PAH e-booth. By spotting possible signs of PAH early on and through routine screening, your patients' survival rates and long-term outcomes may be significantly improved.³

[Visit our e-booth today](#)

CTD, connective tissue disease; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis

1. Rhee RL *et al. Am J Respir Crit Care* 2015; 192(9):1111–1117.
2. Kiely DG *et al. Eur Heart J* 2019; 21(Suppl K):K9–K20.
3. Coghlan JG *et al. Ann Rheum Dis* 2014; 73(7):1340–1349.

LIVE PROGRAMME

The listed lectures will be discussed live with attendant Chairpersons and Speakers in the following live discussion sessions. Video of lectures will be available starting **from March 1, 2022** in the section "PRE-RECORDED PRESENTATIONS" in the congress platform.

THURSDAY, MARCH 10

09:15-10:00 // OPENING

10:00-10:30 // DISCUSSION SESSION 1 - ILD

Chairpersons: **S Proudman (Australia), M Kuwana (Japan)**

Insights and recent concepts from IPF translated to SSc ILD	<i>V Cottin (France)</i>
OC 1 - CAN DUAL-ENERGY CT LUNG PERFUSION DETECT ABNORMALITIES AT THE LEVEL OF LUNG CIRCULATION IN SYSTEMIC SCLEROSIS (SSC)? PRELIMINARY EXPERIENCE IN 101 PATIENTS	<i>V Koether (France)</i>
OC 2 - A HISTOGRAM-BASED DENSITOMETRY INDEX TO IDENTIFY AND ASSESS THE SEVERITY OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: APPLICABILITY IN STANDARD AND LOW-DOSE COMPUTED TOMOGRAPHY	<i>C Bruni (Italy)</i>

10:30-11:00 // DISCUSSION SESSION 2 - HEART INVOLVEMENT

Chairpersons: **S Mavrogeni (Greece), L Dagna (Italy)**

Cardiac involvement in SSc versus other Autoimmune diseases	<i>S Plein (UK)</i>
Definition of pHiSSc	<i>C Bruni (Italy)</i>
OC 4 - SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETA2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPONIN T AND MAY HELP TO IDENTIFY PATIENTS WITH CLINICAL PROGRESS IN SSC	<i>L Schumacher (Germany)</i>
OC 5 - CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS MYOCARDITIS: THE VALUE OF T2 MAPPING TO DETECT MYOCARDIAL INFLAMMATION	<i>G De Luca (Italy)</i>
OC 6 - CHANGES IN MICROCIRCULATION ASSESSED BY NAIFOLD VIDEOCAPILLAROSCOPY IN SYSTEMIC SCLEROSIS PATIENTS TREATED BY BIOLOGICS	<i>E Bertoldo (Italy)</i>
OC 7 - FAPI-PET/CT FOR THE ASSESSMENT OF SYSTEMIC SCLEROSIS-RELATED MYOCARDIAL FIBROSIS	<i>C Bergmann (Germany)</i>

11:00-11:30 // DISCUSSION SESSION 4 - VASCULAR

Chairpersons: **M Hughes (UK), G Riemekasten (Germany)**

Unmet need in the management of peripheral vascular complications	<i>J Pauling (UK)</i>
OC 11 - G-CSF TREATMENT FOR REFRACTORY DIGITAL ULCERS IN SYSTEMIC SCLEROSIS	<i>D Rimar (Israel)</i>
OC 12 - CHORIORETINAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS	<i>PG Cerasuolo (Italy)</i>
OC 13 - PREDICTION OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS BASED ON THE USE OF PLATELET INHIBITORS AND OTHER PARAMETERS - A EUSTAR STUDY ON DERIVATION AND VALIDATION OF A PREDICTION MODEL	<i>A Garaiman (Switzerland)</i>
OC 14 - RELEASE OF HIGH-MOBILITY GROUP BOX-1 AFTER A RAYNAUD'S ATTACK POTENTIALLY LEADS TO FIBROBLAST ACTIVATION AND INTERFERON GAMMA-INDUCED PROTEIN-10 PRODUCTION IN SYSTEMIC SCLEROSIS	<i>IM Atzeni (The Netherlands)</i>

11:30-12:00 // BREAK

12:00-12:30 // DISCUSSION SESSION 5- DEBATE ON KIDNEY INVOLVEMENT

Chairpersons: **D Launay (France), Y Kawaguchi (Japan)**

Renal disease - challenges and recent progress	<i>C Denton (UK)</i>
Recent advances in renal transplantation in SSc: data from the EU register	<i>A D Salama (UK)</i>

12:30-13:00 // DISCUSSION SESSION 3 - PULMONARY ARTERIAL HYPERTENSION

Chairpersons: **M Matucci-Cerinic (Italy), E Hachulla (France)**

From pathophysiology to novel therapeutic targets for PAH	<i>M Humbert (France)</i>
OC 8 - NAILFOLD CAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS- ASSOCIATED PULMONARY HYPERTENSION; PROFILING OF NON-INVASIVE MARKERS, A COHORT STUDY	<i>J Lemmers (The Netherlands)</i>
OC 9 - PULMONARY VASCULAR VOLUME ON HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN THE PREDICTION OF PRE-CAPILLARY PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS	<i>C Bruni (Italy)</i>
OC 10 - SERUM LEVELS OF THE SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS ARE PROSPECTIVELY ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS	<i>IM Atzeni (The Netherlands)</i>

13:00-13:30 // DISCUSSION SESSION 6 - EARLY CLINICAL TRIALS & OUTCOME MEASURES

Chairpersons: **EB Lee (South Korea), M Vonk (The Netherlands)**

White paper	<i>P Merkel (USA) & D Khanna (USA)</i>
OC 15 - SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI): ASSESSMENT OF PROGRESSION IN A SINGLE CENTER COHORT	<i>Y Yancilkaya (Turkey)</i>
OC 16 - MOBILIZATION WITH REDUCED CYCLOPHOSPHAMIDE DOSE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION	<i>AC Pecher (Germany)</i>
OC 17 - DOMAINS AND OUTCOME MEASURES FOR THE ASSESSMENT OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: AN INTERNATIONAL COLLABORATIVE SCOPING REVIEW	<i>A Lescoat (France)</i>
OC 18 - CLINICAL WORSENING FOLLOWING TAPERING OR WITHDRAWAL OF TOCILIZUMAB IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A REAL-WORLD EXPERIENCE	<i>Y Isomura (Japan)</i>
OC 19 - PREDICTORS OF MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS	<i>E Dourado (Portugal)</i>

13:30-15:00 // LIVE BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM FROM RESEARCH TO INDIVIDUAL PATIENT CARE: CLINICAL DECISION-MAKING IN SSC-ILD

Chairpersons: **C Denton (UK), O Distler (Switzerland)**

13:30-13:35 - Welcome and introduction	<i>O Distler (Switzerland)</i>
13:35-14:15 - Multidisciplinary discussion of SSc-ILD: from research to individual patient care	<i>O Distler (Switzerland), A-M Hoffmann-Vold (Norway) & T Maher (USA)</i>
14:15-14:35 - Clinical decision making in SSc-ILD: what has changed?	<i>C Denton (UK) & V Smith (Belgium)</i>
14:35-14:55 - Panel discussion moderated by C. Denton	<i>All</i>
14:55-15:00 - Close	<i>O Distler (Switzerland)</i>

15:00-15:30 - DISCUSSION SESSION 2 - HEART INVOLVEMENT

Chairpersons: **M Hinchcliff (USA), L Dagna (Italy)**

Cardiac involvement in SSc versus other Autoimmune diseases	<i>S Plein (UK)</i>
Definition of pHiSSc	<i>C Bruni (Italy)</i>
OC 4 - SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETA2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPONIN T AND MAY HELP TO IDENTIFY PATIENTS WITH CLINICAL PROGRESS IN SSC	<i>L Schumacher (Germany)</i>
OC 5 - CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS MYOCARDITIS: THE VALUE OF T2 MAPPING TO DETECT MYOCARDIAL INFLAMMATION	<i>G De Luca (Italy)</i>
OC 6 - CHANGES IN MICROCIRCULATION ASSESSED BY NAIFOLD VIDEOCAPILLAROSCOPY IN SYSTEMIC SCLEROSIS PATIENTS TREATED BY BIOLOGICS	<i>E Bertoldo (Italy)</i>
OC 7 - FAPI-PET/CT FOR THE ASSESSMENT OF SYSTEMIC SCLEROSIS-RELATED MYOCARDIAL FIBROSIS	<i>C Bergmann (Germany)</i>

15:30-16:00 // DISCUSSION SESSION 6 - EARLY CLINICAL TRIALS & OUTCOME MEASURES

Chairpersons: **D Furst (USA), M Baron (Canada)**

White paper	<i>P Merkel (USA)</i>
OC 15 - SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI): ASSESSMENT OF PROGRESSION IN A SINGLE CENTER COHORT	<i>Y Yancilkaya (Turkey)</i>
OC 16 - MOBILIZATION WITH REDUCED CYCLOPHOSPHAMIDE DOSE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION	<i>AC Pecher (Germany)</i>
OC 17 - DOMAINS AND OUTCOME MEASURES FOR THE ASSESSMENT OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: AN INTERNATIONAL COLLABORATIVE SCOPING REVIEW	<i>A Lescoat (France)</i>
OC 18 - CLINICAL WORSENING FOLLOWING TAPERING OR WITHDRAWAL OF TOCILIZUMAB IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A REAL-WORLD EXPERIENCE	<i>Y Isomura (Japan)</i>
OC 19 - PREDICTORS OF MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS	<i>E Dourado (Portugal)</i>

16:00-16:30 // DISCUSSION SESSION 4 - VASCULAR

Chairpersons: **F Boin (USA), M Matucci-Cerinic (Italy)**

Unmet need in the management of peripheral vascular complications	<i>J Pauling (UK) & T Frech (USA)</i>
OC 11 - G- CSF TREATMENT FOR REFRACTORY DIGITAL ULCERS IN SYSTEMIC SCLEROSIS	<i>D Rimar (Israel)</i>
OC 12 - CHORIORETINAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS	<i>PG Cerasuolo (Italy)</i>
OC 13 - PREDICTION OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS BASED ON THE USE OF PLATELET INHIBITORS AND OTHER PARAMETERS - A EUSTAR STUDY ON DERIVATION AND VALIDATION OF A PREDICTION MODEL	<i>A Garaiman (Switzerland)</i>
OC 14 - RELEASE OF HIGH-MOBILITY GROUP BOX-1 AFTER A RAYNAUD'S ATTACK POTENTIALLY LEADS TO FIBROBLAST ACTIVATION AND INTERFERON GAMMA-INDUCED PROTEIN-10 PRODUCTION IN SYSTEMIC SCLEROSIS	<i>IM Atzeni (The Netherlands)</i>

16:30-17:00 // DISCUSSION SESSION 5- DEBATE ON KIDNEY INVOLVEMENT

Chairpersons: **J De Vries-Bouwstra (The Netherlands), J Pope (Canada)**

Renal disease - challenges and recent progress	<i>C Denton (UK)</i>
Recent advances in renal transplantation in SSc: data from the EU register	<i>A D Salama (UK)</i>

17:00-17:30 // DISCUSSION SESSION 1 - ILD

Chairpersons: **S Tomassetti (Italy), E Volkman (USA)**

Pathophysiology of ILD	<i>M Kolb (Canada)</i>
Insights and recent concepts from IPF translated to SSc ILD	<i>V Cottin (France)</i>
Changing landscape for treatment SSc ILD	<i>E Volkman (USA)</i>
OC 1 - CAN DUAL-ENERGY CT LUNG PERFUSION DETECT ABNORMALITIES AT THE LEVEL OF LUNG CIRCULATION IN SYSTEMIC SCLEROSIS (SSC)? PRELIMINARY EXPERIENCE IN 101 PATIENTS	<i>V. Koether (France)</i>
OC 2 - A HISTOGRAM-BASED DENSITOMETRY INDEX TO IDENTIFY AND ASSESS THE SEVERITY OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: APPLICABILITY IN STANDARD AND LOW-DOSE COMPUTED TOMOGRAPHY	<i>C Bruni (Italy)</i>
OC 3 - INCREASED EXPRESSION AND PROFIBROTIC EFFECTS OF LIM AND CYSTEINE-RICH DOMAINS-1 PROTEIN IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE (abs 241)	<i>G Bogatkevich (USA)</i>

17:30-18:00 // DISCUSSION SESSION 3 - PULMONARY ARTERIAL HYPERTENSION

Chairpersons: **Y Allanore (France), P Hassoun (USA)**

From pathophysiology to novel therapeutic targets for PAH	<i>M Humbert (France)</i>
OC 8 - NAILFOLD-CAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS- ASSOCIATED PULMONARY HYPERTENSION; PROFILING OF NON-INVASIVE MARKERS, A COHORT STUDY	<i>J Lemmers (The Netherlands)</i>
OC 9 - PULMONARY VASCULAR VOLUME ON HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN THE PREDICTION OF PRE-CAPILLARY PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS	<i>C Bruni (Italy)</i>
OC 10 - SERUM LEVELS OF THE SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS ARE PROSPECTIVELY ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS	<i>IM Atzeni (The Netherlands)</i>

FRIDAY, MARCH 11

10:00-10:30 // DISCUSSION SESSION 8 - MESENCHYMAL BASIC SCIENCE

Chairpersons: **H Yasuoka (Japan), T Krieg (Germany)**

Fibroblast Dysfunction in SSC	<i>J Distler (Germany)</i>
OC 25 - EVOLUTION OF SKIN INFLAMMATORY AND FIBROTIC PARAMETERS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS	<i>A Collet (France)</i>
OC 26 - TGF-BETA/WNT3A DEPENDENT TRANSCRIPTION OF THE HEDGEHOG TRANSCRIPTION FACTORS INITIATES THE EXPRESSION OF THE CHLORIDE INTRACELLULAR CHANNEL 4 (CLIC4) IN SSC FIBROBLASTS	<i>C Wasson (UK)</i>
OC 27 - ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING	<i>A-E Györfi (Germany)</i>
OC 28 - IMPAIRED TFAM EXPRESSION PROMOTES MITOCHONDRIAL DAMAGE TO DRIVE FIBROBLAST ACTIVATION AND FIBROSIS IN SYSTEMIC SCLEROSIS	<i>X Zhou (Germany)</i>

10:30-11:00 // DISCUSSION SESSION 10 - VASCULOPATHY AND CIRCULATING BIOMARKERS

Chairpersons: **A Herrick (UK), M Iudici (Switzerland)**

Endothelial Cell Dysfunction in the Pathogenesis of SSC	<i>Y Asano (Japan)</i>
OC 32 - PHENOTYPE OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS HAVING POSITIVE ANTI-TOPOISOMERASE ANTIBODIES: DATA FROM EUSTAR COHORT	<i>E Zanatta (Italy)</i>
OC 33 - SERUM IFN SCORE PREDICTS LONG TERM OUTCOME IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS	<i>R Karanth U (UK)</i>

11:00-11:30 // DISCUSSION SESSION 19 - FREE BASIC ORAL COMMUNICATIONS

Chairpersons: **G Zhang (China), J Wang (China), M Manetti (Italy), Y Yamaguchi (Japan)**

OC 56 - SILDENAFIL IMPROVES THE REDOX HOMEOSTASIS AND PRO-INFLAMMATORY ACTIVATION IN SYSTEMIC SCLEROSIS FIBROBLASTS EXPOSED TO REACTIVE OXYGEN SPECIES	<i>C Antinozzi (Italy)</i>
OC 57 - A SELECTIVE TGF-B1 AND TGF-B3 TRAP DEMONSTRATES TARGET ENGAGEMENT AND ANTI-FIBROTIC EFFICACY IN MOUSE AND TRANSLATIONAL MODELS OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	<i>T Barr (UK)</i>
OC 58 - TREATMENT WITH ANTI-S100A4 MONOCLONAL ANTIBODIES AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NONINFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS	<i>M Tomcik (Czech Republic)</i>
OC 59 - EVALUATING NOVEL THERAPEUTIC PEPTIDE RP832C TARGETING CD206 IN MODELS OF SCLERODERMA MACROPHAGE-DEPENDENT FIBROSIS AND INFLAMMATION	<i>R Stratton (UK)</i>
OC 60 - IMPAIRED DIGESTION OF CIRCULATING GENOMIC DNA IN SYSTEMIC SCLEROSIS PATIENTS AND HEALTHY CONTROLS WITH THE DNASE1L3 R206C VARIANT	<i>B Skaug (USA)</i>
OC 61 - ANTIGEN-SPECIFIC, AUTO-REACTIVE B CELL RESPONSES REVEAL DIFFERENTIAL IMMUNOLOGICAL ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>HU Scherer (The Netherlands)</i>
OC 62 - SUPERB MICROVASCULAR IMAGING AS A NOVEL IMAGING TOOL FOR THE QUANTIFICATION OF FINGER TIP BLOOD FLOW IN SYSTEMIC SCLEROSIS	<i>P Korsten (Germany)</i>

11:30-12:00 • BREAK

12:00-12:30 // DISCUSSION SESSION 12 - BEST FROM JOURNALS

NATURE

Chairperson: **S Onuora (UK)**

Detection of microvascular changes in systemic sclerosis and other rheumatic diseases

M Cutolo (Italy)

RHEUMATOLOGY

Chairperson: **M Bukhari (UK)**

Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort

M Hughes (UK)

JSRD

Chairperson: **M Kuwana (Japan)**

Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth

M Larché (Canada)

LANCET RHEUMATOLOGY

Chairperson: **H Van Epps (UK)**

Progression to Systemic Sclerosis in patients with Raynaud's: stratified risk models for clinical management and prevention trials

F Del Galdo (UK)

12:30-13:00 // DISCUSSION SESSION 14 -COMPREHENSIVE CARE OF THE PATIENT WITH SSC IN THE WORLD

Chairpersons: **S. Farrington (UK), I Galetti (Italy)**

Consensus Best Practice Pathways for SSc treatment with a focus patient

M Buch (UK)

Diffuse Skin disease versus limited skin involvement - treatment options and management strategies in Australia" with a patient

S Proudman (Australia)

13:00-13:30 // DISCUSSION SESSION 7 - THERAPY IN SSC

Chairpersons: **S Proudman (Australia), C Denton (UK)**

Evolution of therapies in SSC, from the first treatment to the present reality	<i>J Seibold (USA)</i>
OC 20 - NINTEDANIB (NTD) REAL-LIFE EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) INTERSTITIAL LUNG DISEASE (ILD): AN ITALIAN MULTICENTRE PRELIMINARY STUDY	<i>C Campochiaro (Italy)</i>
OC 21 - RISK STRATIFICATION AND TREATMENT REGIMENS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION	<i>HJ Bjørkekjær (Norway)</i>
OC 22 - EFFECTS OF NINTEDANIB IN SUBJECTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (LCSSC) AND INTERSTITIAL LUNG DISEASE (ILD): DATA FROM THE SENSISC TRIAL	<i>Y Allanore (France)</i>
OC 23 - EFFECT OF AN 8-WEEK PHYSICAL THERAPY PROGRAM ON SEXUAL FUNCTION IN WOMEN WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY	<i>B Hermankova (Czech Republic)</i>
OC 24 - IMPROVEMENT IN SKIN AND PULMONARY FUNCTION TESTS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS TREATED WITH BRENTUXIMAB VEDOTIN; INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL	<i>A Fernandez-Codina (Canada)</i>

13:30-15:00 // LIVE JANSSEN SATELLITE SYMPOSIUM MANAGEMENT OF CTD-PAH: A MULTIDISCIPLINARY APPROACH

Chairpersons: **S Gaine (Ireland), A-M Hoffmann-Vold (Norway)**

13:30-13:35 - Welcome and introduction	<i>A-M Hoffmann-Vold (Norway)</i>
13:35-13:55 - Pearls and pitfalls: Screening and diagnosis of PAH in SSC patients	<i>S Guiducci (Italy)</i>
13:55-14:35 - Roundtable discussion: The importance of timely treatment and a multidisciplinary approach for SSC-PAH patients	<i>O Distler (Switzerland) & J-L Vachiéry (Belgium)</i>
14:35-14:50 - Q&A: panel discussion and audience questions	<i>All</i>
14:50-15:00 - Key messages and closing remarks	<i>S Gaine (Ireland)</i>

15:00-15:30 // DISCUSSION SESSION 10 - VASCULOPATHY AND CIRCULATING BIOMARKERS

Chairpersons: **L Chung (USA), V Sobanski (France)**

OC 32 - PHENOTYPE OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS HAVING POSITIVE ANTI-TOPOISOMERASE ANTIBODIES: DATA FROM EUSTAR COHORT	<i>E Zanatta (Italy)</i>
OC 33 - SERUM IFN SCORE PREDICTS LONG TERM OUTCOME IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS	<i>R Karanth U (UK)</i>
OC 34 - SERUM PROTEIN INTERFERON SCORE IS BIOMARKER OF ACTIVE DISEASE IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS ENROLLED IN PROSPECTIVE REGISTRY OF EARLY SYSTEMIC SCLEROSIS (PRESS) COHORT	<i>M Hinchcliff (USA)</i>

15:30-16:00 // DISCUSSION SESSION 19 - FREE BASIC ORAL COMMUNICATIONS

Chairpersons: **E Romano (Italy), K Clark (UK), ME Truchetet (France), M Tomcik (Czech Republic)**

OC 56 - SILDENAFIL IMPROVES THE REDOX HOMEOSTASIS AND PRO-INFLAMMATORY ACTIVATION IN SYSTEMIC SCLEROSIS FIBROBLASTS EXPOSED TO REACTIVE OXYGEN SPECIES	<i>C Antinozzi (Italy)</i>
OC 57 - A SELECTIVE TGF-B1 AND TGF-B3 TRAP DEMONSTRATES TARGET ENGAGEMENT AND ANTI-FIBROTIC EFFICACY IN MOUSE AND TRANSLATIONAL MODELS OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	<i>T Barr (UK)</i>
OC 58 - TREATMENT WITH ANTI-S100A4 MONOCLONAL ANTIBODIES AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NONINFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS	<i>M Tomcik (Czech Republic)</i>
OC 59 - EVALUATING NOVEL THERAPEUTIC PEPTIDE RP832C TARGETING CD206 IN MODELS OF SCLERODERMA MACROPHAGE-DEPENDENT FIBROSIS AND INFLAMMATION	<i>R Stratton (UK)</i>
OC 60 - IMPAIRED DIGESTION OF CIRCULATING GENOMIC DNA IN SYSTEMIC SCLEROSIS PATIENTS AND HEALTHY CONTROLS WITH THE DNASE1L3 R206C VARIANT	<i>B Skaug (USA)</i>
OC 61 - ANTIGEN-SPECIFIC, AUTO-REACTIVE B CELL RESPONSES REVEAL DIFFERENTIAL IMMUNOLOGICAL ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>HU Scherer (The Netherlands)</i>
OC 62 - SUPERB MICROVASCULAR IMAGING AS A NOVEL IMAGING TOOL FOR THE QUANTIFICATION OF FINGER TIP BLOOD FLOW IN SYSTEMIC SCLEROSIS	<i>P Korsten (Germany)</i>

16:00-16:30 // DISCUSSION SESSION 14 - COMPREHENSIVE CARE OF THE PATIENT WITH SSC IN THE WORLD

Chairpersons: **S. Farrington (UK), I Galetti (Italy)**

Consensus Best Practice Pathways for SSc treatment with a focus patient	<i>M Buch (UK)</i>
SSc-ILD monitoring in the U.S with a patient	<i>M Mayes (USA)</i>

16:30-17:00 // DISCUSSION SESSION 12 - BEST FROM JOURNALS

A&R

Chairperson: **D Solomon (USA)**

Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease	<i>D Roofeh (USA)</i>
---	-----------------------

NATURE

Chairperson: **S Onuora (UK)**

Detection of microvascular changes in systemic sclerosis and other rheumatic diseases	<i>M Cutolo (Italy)</i>
---	-------------------------

RHEUMATOLOGY

Chairperson: **M Bukhari (UK)**

Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort	<i>M Hughes (UK)</i>
---	----------------------

LANCET RHEUMATOLOGY

Chairperson: **H Van Epps (UK)**

Progression to Systemic Sclerosis in patients with Raynaud's: stratified risk models for clinical management and prevention trials	<i>F Del Galdo (UK)</i>
--	-------------------------

17:00-17:30 // DISCUSSION SESSION 7 - THERAPY IN SSC

Chairpersons: **D Khanna (USA), C Denton (UK)**

Evolution of therapies in SSc, from the first treatment to the present reality	<i>J Seibold (USA)</i>
OC 20 - NINTEDANIB (NTD) REAL-LIFE EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC)-INTERSTITIAL LUNG DISEASE (ILD): AN ITALIAN MULTICENTRE PRELIMINARY STUDY	<i>C Campochiaro (Italy)</i>
OC 21 - RISK STRATIFICATION AND TREATMENT REGIMENS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION	<i>HJ Bjørkekjær (Norway)</i>
OC 22 - EFFECTS OF NINTEDANIB IN SUBJECTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (LCSSC) AND INTERSTITIAL LUNG DISEASE (ILD): DATA FROM THE SENSISC TRIAL	<i>Y Allanore (France)</i>
OC 23 - EFFECT OF AN 8-WEEK PHYSICAL THERAPY PROGRAM ON SEXUAL FUNCTION IN WOMEN WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY	<i>B Hermankova (Czech Republic)</i>
OC 24 - IMPROVEMENT IN SKIN AND PULMONARY FUNCTION TESTS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS TREATED WITH BRENTUXIMAB VEDOTIN; INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL	<i>A Fernandez-Codina (Canada)</i>

17:30-18:00 // DISCUSSION SESSION 8 - MESENCHYMAL BASIC SCIENCE

Chairpersons: **J van Laar (The Netherlands), S Assassi (USA)**

Fibroblast Dysfunction in SSc	<i>J Distler (Germany)</i>
OC 25 - EVOLUTION OF SKIN INFLAMMATORY AND FIBROTIC PARAMETERS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS	<i>A Collet (France)</i>
OC 26 - TGF-BETA/WNT3A DEPENDENT TRANSCRIPTION OF THE HEDGEHOG TRANSCRIPTION FACTORS INITIATES THE EXPRESSION OF THE CHLORIDE INTRACELLULAR CHANNEL 4 (CLIC4) IN SSC FIBROBLASTS	<i>C Wasson (UK)</i>
OC 27 - ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING	<i>A-E Györfi (Germany)</i>
OC 28 - IMPAIRED TFAM EXPRESSION PROMOTES MITOCHONDRIAL DAMAGE TO DRIVE FIBROBLAST ACTIVATION AND FIBROSIS IN SYSTEMIC SCLEROSIS	<i>X Zhou (Germany)</i>

18:00-18:30 // LIVE MALLINCKRODT PHARMACEUTICALS SATELLITE SYMPOSIUM

The mechanism of action and role of ECP in treating Systemic Sclerosis	<i>R Gnidecki (Canada)</i>
--	----------------------------

SATURDAY, MARCH 12

10:30-11:00 // DISCUSSION SESSION 13 - GI

Chairpersons: **S Bellando Randone (Italy), X Zeng (China)**

Gastrointestinal involvement in SSc: State-of-the art and recent knowledge about disease pathogenesis	<i>U Mueller-Ladner (Germany)</i>
OC 39 - USE AND PERCEPTIONS OF NUTRITION INFORMATION RESOURCES AMONG PEOPLE WITH SYSTEMIC SCLEROSIS FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT (abs 2)	<i>N Østbø (Canada)</i>
OC 40 - PREVALENCE OF GASTROINTESTINAL MANIFESTATIONS IN AN AUSTRALIAN SCLERODERMA COHORT	<i>A Quinlivan (Australia)</i>
OC 41 - THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI) IN A SYSTEMIC SCLEROSIS COHORT WITH 10-YEARS FOLLOW-UP	<i>MG Lazzaroni (Italy)</i>

11:00-11:30 // DISCUSSION SESSION 15 - SYSTEMIC SCLEROSIS, PREGNANCY AND SEXUAL HEALTH

Chairpersons: **A Balbir-Gurmann (Israel), P Carreira (Spain)**

Outcomes in SSc pregnancies	<i>E Tombetti (Italy)</i>
OC 42 - THE IMPACT OF SYSTEMIC SCLEROSIS ON WOMEN HEALTH: CREATION AND ADMINISTRATION OF A NEW SSC-SPECIFIC PATIENT-REPORTED QUESTIONNAIRE	<i>MG Lazzaroni (Italy)</i>
OC 43 - SEXUAL FUNCTION IN MEN WITH SYSTEMIC SCLEROSIS	<i>B Hermankova (Czech Republic)</i>

11:30-12:00 // DISCUSSION SESSION 16 - COVID AND SSC

Chairpersons: **A Gabrielli (Italy), MT Li (China)**

After the COVID storm: Vaccinations in SSc	<i>Y Braun-Moscovici (Israel)</i>
OC 44 - RISK ASSESSMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASES DURING COVID-19 PANDEMIC: IS DISTANCE ASSESSMENT POSSIBLE?	<i>A Volkov (Russia)</i>
OC 45 - IMMUNOGENICITY OF A SINGLE DOSE OF COVID-19 VACCINATION IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH OR WITHOUT IMMUNOSUPPRESSION	<i>V Kakkar (UK)</i>
OC 46 - PROSPECTIVE CONTROLLED TRIAL OF IMMUNOGENICITY AND SAFETY OF AN INACTIVATED VIRUS VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>P Sampaio Barros (Brazil)</i>
OC 47 - THE CHARACTERISTICS OF GROUND GLASS OPACIFICATION AT COMPUTED TOMOGRAPHY MAY ALLOW A DIFFERENTIAL DIAGNOSIS BETWEEN INTERSTITIAL LUNG DISEASE BETWEEN COVID-19 AND SYSTEMIC SCLEROSIS	<i>M Orlandi (Italy)</i>
OC 48 - THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS REGISTERED IN THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR)	<i>A Hoffmann-Vold (Norway)</i>

12:00-12:30 // BREAK

12:30-13:00 // DISCUSSION SESSION 18 - FREE CLINICAL ORAL COMMUNICATIONS

Chairpersons: **Y Suliman (Egypt), S Bosello (Italy), J Colic (Serbia), J Spierings (The Netherlands)**

OC 49 - PREDICTIVE VALUE OF ULTRASOUND PARAMETERS OF THE HAND ON THE ONSET OF CLINICAL MANIFESTATIONS DURING LONGITUDINAL FOLLOW-UP IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>L Thibaut (France)</i>
OC 50 - ALTERATIONS OF LIPID PROFILE IN SCLERODERMA PATIENTS AND THE ASSOCIATIONS WITH DISEASE-SPECIFIC FEATURES	<i>S Oreska (Czech Republic)</i>
OC 52 - RAYNAUD'S PHENOMENON: EPIDEMIOLOGICAL, CLINICAL, DERMOSCOPIC, ETIOLOGICAL ASPECTS AND THERAPEUTIC MANAGEMENT IN LIVING BLACK SKIN PATIENTS IN TROPICAL AREAS	<i>F Ly (Senegal)</i>
OC 54 - IMPROVEMENT WITH TIME OF VASCULAR OUTCOMES IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY	<i>M Hughes (UK)</i>
OC 55 - PREDICTORS OF HOSPITALIZATION IN PATIENTS WITH SYSTEMIC SCLEROSIS: A 12-YEAR COHORT STUDY OF 170 PATIENTS FROM A TERTIARY CENTER	<i>H Assunção (Portugal)</i>

13:00-13:30 // DISCUSSION SESSION 9 - THE IMMUNE SYSTEM IN SYSTEMIC SCLEROSIS

Chairpersons: **D Daoussis (Greece), T Krieg (Germany)**

B Cells in SSc	<i>L Sakkas (Greece)</i>
OC 29 - IL-2-RELATED REGULATORY CD4 T-CELL DEFICIENCY LEADS TO THE DEVELOPMENT OF LUNG FIBROSIS AND VASCULAR REMODELING	<i>C Frantz (France)</i>
OC 30 - AUTOANTIBODIES FROM SYSTEMIC SCLEROSIS PATIENTS TARGETING THE ANGIOTENSIN II TYPE 1 AND ENDOTHELIN-1 TYPE A RECEPTOR INDUCE ENDOTHELIAL CELL ACTIVATION AND PRO-FIBROTIC RESPONSES	<i>C Fehres (The Netherlands)</i>
OC 31 - HUMORAL RESPONSE TO BNT162B2 MRNA VACCINE AGAINST SARS COV2, IN SYSTEMIC SCLEROSIS PATIENTS AND THE IMPACT ON THE RHEUMATIC DISEASE ACTIVITY	<i>A Balbir-Gurman (Israel)</i>

13:30-14:00 // DISCUSSION SESSION 11 - FRONTIERS IN SCIENCE

Chairpersons: **D Abraham (UK), C Bellocchi (Italy)**

Single Cell Gene Expression Profiling in SSc	<i>R Lafyatis (USA)</i>
Single-cell and spatial-seq integration in scleroderma - novel insights	<i>J Gudjonsson (USA)</i>
OC 35 - CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSC: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION	<i>F Del Galdo (UK)</i>
OC 36 - ESTABLISHMENT AND CHARACTERIZATION OF 3D LUNG ORGANOIDs GENERATED FROM A MURINE MODEL OF SYSTEMIC SCLEROSIS	<i>V. Koether (France)</i>
OC 37 - PATHWAY ANALYSIS FROM WHOLE BLOOD TRANSCRIPTOME REVEALS UNIQUE CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS AT THE PRECLINICAL STAGE	<i>C Bellocchi (Italy)</i>
OC 38 - PERIPHERAL BLOOD GENE EXPRESSION PROFILING PREDICTS RESPONSE TO MYCOPHENOLATE IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE	<i>S Assassi (USA)</i>

14:00-14:30 // LIVE TALARIS THERAPEUTICS SATELLITE SYMPOSIUM HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) AS TREATMENT IN SYSTEMIC SCLEROSIS

Rationale for HSCT in early SSc	<i>D Khanna (USA)</i>
Expanding options in cellular therapy in SSc	<i>K Sullivan (USA)</i>

14:30-15:00 // DISCUSSION SESSION 18 - FREE CLINICAL ORAL COMMUNICATIONS

Chairpersons: **D Giuggioli (Italy), V Nagaraja (USA), AM Gheorghiu (Romania), T Minier (Hungary)**

OC 49 - PREDICTIVE VALUE OF ULTRASOUND PARAMETERS OF THE HAND ON THE ONSET OF CLINICAL MANIFESTATIONS DURING LONGITUDINAL FOLLOW-UP IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>L Thibaut (France)</i>
OC 50 - ALTERATIONS OF LIPID PROFILE IN SCLERODERMA PATIENTS AND THE ASSOCIATIONS WITH DISEASE-SPECIFIC FEATURES	<i>S Oreska (Czech Republic)</i>
OC 51 - SCLERODERMA IN INDIVIDUALS WITH EXPOSURE TO WORLD TRADE CENTER GROUND-ZERO AND/OR RESCUE/RECOVERY EFFORTS: A CASE SERIES	<i>M Own (USA)</i>
OC 52 - RAYNAUD'S PHENOMENON: EPIDEMIOLOGICAL, CLINICAL, DERMOSCOPIC, ETIOLOGICAL ASPECTS AND THERAPEUTIC MANAGEMENT IN LIVING BLACK SKIN PATIENTS IN TROPICAL AREAS	<i>F Ly (Senegal)</i>
OC 54 - IMPROVEMENT WITH TIME OF VASCULAR OUTCOMES IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY	<i>M Hughes (UK)</i>
OC 55 - PREDICTORS OF HOSPITALIZATION IN PATIENTS WITH SYSTEMIC SCLEROSIS: A 12-YEAR COHORT STUDY OF 170 PATIENTS FROM A TERTIARY CENTER	<i>H Assunção (Portugal)</i>

15:00-15:30 // DISCUSSION SESSION 16 - COVID AND SSC

Chairpersons: **Y Levy (Israel), L Dagna (Italy)**

After the COVID storm: vaccinations in SSc	<i>Y Braun-Moscovici (Israel)</i>
Is the new variant changing anything in this pandemic?	<i>K Winthrop (USA)</i>
OC 44 - RISK ASSESSMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASES DURING COVID-19 PANDEMIC: IS DISTANCE ASSESSMENT POSSIBLE?	<i>A Volkov (Russia)</i>
OC 45 - IMMUNOGENICITY OF A SINGLE DOSE OF COVID-19 VACCINATION IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH OR WITHOUT IMMUNOSUPPRESSION	<i>V Kakkar (UK)</i>
OC 46 - PROSPECTIVE CONTROLLED TRIAL OF IMMUNOGENICITY AND SAFETY OF AN INACTIVATED VIRUS VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC SCLEROSIS	<i>P Sampaio Barros (Brazil)</i>
OC 47 - THE CHARACTERISTICS OF GROUND GLASS OPACIFICATION AT COMPUTED TOMOGRAPHY MAY ALLOW A DIFFERENTIAL DIAGNOSIS BETWEEN INTERSTITIAL LUNG DISEASE BETWEEN COVID-19 AND SYSTEMIC SCLEROSIS	<i>M Orlandi (Italy)</i>
OC 48 - THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS REGISTERED IN THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR)	<i>A Hoffmann-Vold (Norway)</i>

15:30-16:00 // DISCUSSION SESSION 13 - GI

Chairpersons: **L Mouthon (France), A Makol (USA)**

Gastrointestinal involvement in SSc: State-of-the art and recent knowledge about disease pathogenesis	<i>U Mueller-Ladner (Germany)</i>
Overview on the recent clinical trial and studies in GI SSc	<i>Z McMahan (USA)</i>
OC 39 - USE AND PERCEPTIONS OF NUTRITION INFORMATION RESOURCES AMONG PEOPLE WITH SYSTEMIC SCLEROSIS FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT (abs 2)	<i>N Østbø (Canada)</i>
OC 41 - THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI) IN A SYSTEMIC SCLEROSIS COHORT WITH 10-YEARS FOLLOW-UP	<i>MG Lazzaroni (Italy)</i>

16:00-16:30 // DISCUSSION SESSION 15 - SYSTEMIC SCLEROSIS, PREGNANCY AND SEXUAL HEALTH

Chairpersons: **M Mayes (USA), G Szusc (Hungary)**

Outcomes in SSc pregnancies	<i>E Tombetti (Italy)</i>
Challenges of diagnosing Scleroderma renal crisis in Scleroderma pregnancies	<i>V Steen (USA)</i>
OC 42 - THE IMPACT OF SYSTEMIC SCLEROSIS ON WOMEN HEALTH: CREATION AND ADMINISTRATION OF A NEW SSC-SPECIFIC PATIENT-REPORTED QUESTIONNAIRE	<i>MG Lazzaroni (Italy)</i>
OC 43 - SEXUAL FUNCTION IN MEN WITH SYSTEMIC SCLEROSIS	<i>B Hermankova (Czech Republic)</i>

16:30-17:00 // DISCUSSION SESSION 9 - THE IMMUNE SYSTEM IN SYSTEMIC SCLEROSIS

Chairpersons: **GL Moroncini (Italy), M Trojanowska (USA)**

B Cells in SSc	<i>L Sakkas (Greece)</i>
OC 29 - IL-2-RELATED REGULATORY CD4 T-CELL DEFICIENCY LEADS TO THE DEVELOPMENT OF LUNG FIBROSIS AND VASCULAR REMODELING	<i>C Frantz (France)</i>
OC 30 - AUTOANTIBODIES FROM SYSTEMIC SCLEROSIS PATIENTS TARGETING THE ANGIOTENSIN II TYPE 1 AND ENDOTHELIN-1 TYPE A RECEPTOR INDUCE ENDOTHELIAL CELL ACTIVATION AND PRO-FIBROTIC RESPONSES	<i>C Fehres (The Netherlands)</i>
OC 31 - HUMORAL RESPONSE TO BNT162B2 MRNA VACCINE AGAINST SARS COV2, IN SYSTEMIC SCLEROSIS PATIENTS AND THE IMPACT ON THE RHEUMATIC DISEASE ACTIVITY	<i>A Balbir-Gurman (Israel)</i>

17:00-17:30 // DISCUSSION SESSION 11 - FRONTIERS IN SCIENCE

Chairpersons: **J Varga (USA), F Del Galdo (UK)**

Single-cell and spatial-seq integration in scleroderma - novel insights	<i>J Gudjonsson (USA)</i>
OC 35 - CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSC: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION	<i>F Del Galdo (UK)</i>
OC 36 - ESTABLISHMENT AND CHARACTERIZATION OF 3D LUNG ORGANIDS GENERATED FROM A MURINE MODEL OF SYSTEMIC SCLEROSIS	<i>V. Koether (France)</i>
OC 37 - PATHWAY ANALYSIS FROM WHOLE BLOOD TRANSCRIPTOME REVEALS UNIQUE CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS AT THE PRECLINICAL STAGE	<i>C Bellocchi (Italy)</i>
OC 38 - PERIPHERAL BLOOD GENE EXPRESSION PROFILING PREDICTS RESPONSE TO MYCOPHENOLATE IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE	<i>S Assassi (USA)</i>

17:30-18:00 // SESSION 20 - WRAP UP OF THE CONGRESS

M Kuwana (Japan) & O Distler (Switzerland)

18:00-18:15 // CLOSING

Harness their natural strength^{1,2}

Consider ECP to modulate their dysregulated immune system and support them beyond just symptom control^{*3-6}



***THERAKOS ECP Immunomodulation™ employs the patient's own immune cells to modulate dysregulated immune function^{1-5,7-10}**

For more information about THERAKOS ECP Immunomodulation™, please visit www.therakos.eu

¹ Therakos Operator's Manual. THERAKOS™ CELLEX™ Photopheresis System. ² Hart JW, et al. Ther Adv Hematol. 2013;4:320-334. ³ Wang L, et al. Front Immunol. 2018;9:2207. ⁴ Ni M, et al. Front Immunol. 2019;10:547. ⁵ Mankarious M, et al. Front Immunol. 2020;11:81. ⁶ Dignan FL, et al. Bone Marrow Transplant. 2014;49(5):704-708. ⁷ Yoo EK, et al. J Invest Dermatol. 1996;107:235-242. ⁸ Morelli AE, et al. Blood. 2003;101:611-620. ⁹ Craciun LI, et al. Transplantation. 2002;74:995-1000. ¹⁰ Lamioni A, et al. Transplantation. 2005;79:846-850.

LIVE SATELLITE SYMPOSIA

Satellite Symposia will run live.

THURSDAY, MARCH 10

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

13:30-15:00
**FROM RESEARCH TO INDIVIDUAL PATIENT CARE:
CLINICAL DECISION-MAKING IN SSC-ILD**

Chairpersons: **C Denton (UK) & O Distler (Switzerland)**

13:30-13:35
Welcome and introduction
O Distler (Switzerland)

13:35-14:15
Multidisciplinary discussion of SSC-ILD: from research to individual patient care
O Distler (Switzerland), A-M Hoffmann-Vold (Norway) & T Maher (USA)

14:15-14:35
Clinical decision making in SSC-ILD: what has changed?
C Denton (UK) & V Smith (Belgium)

14:35-14:55
Panel discussion
All moderated by C Denton (UK)

14:55-15:00
Close
O Distler (Switzerland)

FRIDAY, MARCH 11

JANSSEN SATELLITE SYMPOSIUM

13:30-15:00
**MANAGEMENT OF CTD-PAH: A MULTIDISCIPLINARY
APPROACH**

Chairpersons: **S Gainé (Ireland), A-M Hoffmann-Vold (Norway)**

13:30-13:35
Welcome and introduction
A-M Hoffmann-Vold (Norway)

13:35-13:55
Pearls and pitfalls: Screening and diagnosis of PAH in SSc patients
S Guiducci (Italy)

13:55-14:35
Roundtable discussion: The importance of timely treatment and a multidisciplinary approach for SSc-PAH patients
O Distler (Switzerland) & J-L Vachiéry (Belgium)

14:35-14:50
Q&A: panel discussion and audience questions
All

14:50-15:00
Key messages and closing remarks
S Gainé (Ireland)

FRIDAY, MARCH 11

MALLINCKRODT PHARMACEUTICALS SATELLITE SYMPOSIUM

18:00-18:30

THE MECHANISM OF ACTION AND ROLE OF ECP IN
TREATING SYSTEMIC SCLEROSIS

R Gniadecki (Canada)

SATURDAY, MARCH 12

TALARIS THERAPEUTICS SATELLITE SYMPOSIUM

14:00-14:30

HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) AS
TREATMENT IN SYSTEMIC SCLEROSIS

Rationale for HSCT in early SSc

D Khanna (USA)

Expanding options in cellular therapy in SSc

K Sullivan (USA)

POSTER SESSION

Posters will be charged into the platform at disposal for all participant. Authors will have at disposal a 3-minutes recording speech to be integrated to the poster file.

PATHOGENESIS (INCLUDING AUTOANTIBODIES)

- P.001 ROLE OF MACROPHAGE MIGRATORY INHIBITORY FACTOR (MIF) IN SYSTEMIC SCLEROSIS**
DOAA KAMAL, NAEMA MOHAMED, OMNIA BAKR, NADIA ISMAIL, NIHAL FATHI
- P.002 THE INFLAMMATORY CYTOKINE RESPONSE OF PERIPHERAL BLOOD MONONUCLEAR CELLS IS MODULATED BY ANTI-ADRB2 ANTIBODIES DERIVED FROM PATIENTS WITH SYSTEMIC SCLEROSIS**
PAULINA MACKEDANZ, HANNA GRABHOFF, GABRIELE MARSCHNER, SARA COMDUHR, HARALD HEIDECHE, ANTJE MÜLLER, GABRIELA RIEMEKASTEN, ANJA SCHUMANN
- P.003 IGA AUTOANTIBODIES IN SYSTEMIC SCLEROSIS**
ESTIBALIZ RUIZ-ORTIZ, ALBERT PÉREZ-ISIDRO, MARESA GRUNDHUBER, NOEMÍ DE MONER, GEMA M LLEDÓ, GERARD ESPINOSA, ODETTE VIÑAS
- P.004 ANTI-TH/TO AUTO-ANTIBODIES IN PATIENTS WITH SSC: BEYOND COMMERCIAL ASSAYS**
JANIRE PERURENA-PRÍETO, EDUARDO LUIS CALLEJAS-MORAGA, ALFREDO GUILLÉN-DEL-CASTILLO, LAURA VIÑAS-GIMENEZ, M^a TERESA SANZ-MARTÍNEZ, ANA MARÍN-SÁNCHEZ, VICENT FONOLLOSA-PLÁ, ROGER COLOBRAN, CARMEN PILAR SIMEÓN-AZÑAR
- P.005 UNRAVELLING THE ROLE OF INTERLEUKIN-13 IN SYSTEMIC SCLEROSIS**
HANNA GRABHOFF, ANJA SCHUMANN, SARA COMDUEHR, GABRIELA RIEMEKASTEN
- P.006 SEROLOGICAL PROFILE IN SYSTEMIC SCLEROSIS USING THE NEW EXTENDED ANTINUCLLEAR PANEL**
EWA WIEŁOSZ, MAGDALENA DRYGLEWSKA, EWA LYS, MARIA MAJDAN
- P.007 NEW AUTOANTIBODIES AGAINST FGF2-, PLGF AND ADRB1 IN SYSTEMIC SCLEROSIS**
SUSANNE SCHINKE, KRISTINA STERNER, HARRY HEIDECHE, HAUKE BUSCH, AXEL KUENSTNER, INKE KOENIG, CESAIRE JK FOUODO, ANTJE MÜLLER, GABRIELA RIEMEKASTEN
- P.008 SILICONE BREAST IMPLANTS AND SYSTEMIC SCLEROSIS: POSSIBLE ASSOCIATIONS AND PRELIMINARY ANALYSIS OF OUR POPULATION**
GABRIELE AMATI, AMELIA SPINELLA, CLAUDIO GALLUZZO, MARCO DE PINTO, SOFIA TESTONI, MARIA TERESA MASCHIA, CARLO SALVARANI, DILIA GIUGGIOLI
- P.009 ASSOCIATIONS OF ANTI-CENTROMERE ANTIBODY WITH DISEASE SEVERITY AND FUTURE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS**
MELODI GIZEM CAN, YASEMIN YALCINKAYA, BUSRA DEMIR, SHIRKHAN AMIKISHIYEV, NUMUNE ALIYEVA, BAHAR ARTIM-ESEN, AHMET GUL, MURAT INANC
- P.010 GENETIC ASSOCIATIONS OF THE NON-MHC REGION WITH SYSTEMIC SCLEROSIS IN A HAN CHINESE POPULATION**
WEILIN PU, RUI ZHANG, YANYUN MA, QINGMEI LIU, SHUAI JIANG, JING LIU, YINHUAN ZHAO, WENZHEN TU, GANG GUO, XIAOXIA ZUO, QINGWEN WANG, YUANYUAN CHEN, WENYU WU, XIAODONG ZHOU, JORG DISTLER, JOHN REVEILLE, HEJIAN ZOU, LI JIN, MAUREEN MAYES, JIUCUN WANG
- P.011 IMMUNE DISBALANCE, VASCULOPATHY, AND FIBROSIS AS AN ESSENTIAL TRIAD OF SYSTEMIC SCLEROSIS: AN EXPERIMENTAL STUDY**
BOHDANA DOSKALIUK, LIUBOMYR ZAIATS, ROMAN YATSYSHYN
- P.012 PLASMA CONCENTRATION OF AMINO ACIDS RELATED METABOLITES IN PATIENTS WITH SCLERODERMA**
ZANETA SMOLENSKA, JUZANNA GOGULSKA, RYSZARD TOMASZ SMOLENSKI, ZBIGNIEW ZDROJEWSKI
- P.013 CRYOFIBRINOGEN-ASSOCIATED SYSTEMIC SCLEROSIS: OUR PRELIMINARY EXPERIENCE**
GABRIELE AMATI, AMELIA SPINELLA, GILDA SANDRI, PATRIZIA NATALI, DARIA DEBBIA, LAURA BAZZANI, CLAUDIO GALLUZZO, MARCO DE PINTO, SOFIA TESTONI, CARLO SALVARANI, DILIA GIUGGIOLI
- P.014 IMMUNOGLOBULINS G FROM SYSTEMIC SCLEROSIS PATIENTS INDUCE A PROFIBROSING AND SEROTYPE-DEPENDENT PHENOTYPE IN NORMAL DERMAL FIBROBLAST: A MULTI-OMICS STUDY**
AURÉLIEN CHEPY, SOLANGE VIVIER, FABRICE BRAY, MARTIN FIGEAC, JEAN-PASCAL MENEBOO, TERNYNCK CAMILLE, LUCILE GUILBERT, MANEL JENDOUBI, CHRISTIAN ROLANDO, DAVID LAUNAY, SYLVAIN DUBUCQUOI, GUILLEMETTE MAROT, VINCENT SOBANSKI
- P.015 EXPLORATION OF THE ASSOCIATION BETWEEN THE PRESENCE OF VASCULAR AUTOANTIBODIES AND MICROANGIOPATHY IN PATIENTS WITH SYSTEMIC SCLEROSIS**
SOPHIE LIEM, CYNTHIA FEHRES, NINA VAN LEEUWEN, LIESBETH BEAART-VAN DER VOORDE, GABRIELA RIEMEKASTEN, HANS ULRICH SCHERER, RENE TOES, TOM HUIZINGA, JESKA DE VRIES-BOUWSTRA
- P.016 IMPAIRED EFFEROCYTOSIS CAPACITIES OF MONOCYTES DERIVED MACROPHAGES DIFFERENTIATED BY CXCL4: IMPLICATION IN SYSTEMIC SCLEROSIS**
LE TALLEC ERWAN, BELLAMRI NESSRINE, LELONG MARIE, FRENGER QUENTIN, LESCOAT ALAIN, GROS FRÉDÉRIC, LECUREUR VALÉRIE

PATHOGENESIS (INCLUDING AUTOANTIBODIES)

- P.017** **CLINICAL AND AUTOANTIBODY ASSOCIATIONS IN ANA-POSITIVE SYSTEMIC SCLEROSIS LACKING PROTOTYPIC AUTOANTIBODIES**
KAREN KRUZER, ROBERTA GONCALVES MARANGONI, ILANA HECKLER, AYA ELHAGE, JOHN VARGA, MONIQUE HINCHCLIFF, MARY CARNS, KATHLEEN AREN, AMY WIELGOSZ, MARC NUZZO, ISWARIYA VENKATARAMAN, BENJAMIN KORMAN
- P.018** **DESIGN OF A GENE SIGNATURE TO ANALYZE THE PROINFLAMMATORY AND THE PROFIBROTIC POLARIZATION OF MURINE FIBROBLASTS AND VALIDATION IN AN EXPERIMENTAL MURINE MODEL OF SCLERODERMA.**
EMMANUEL LEDOULT, MANEL JENDOUBI, THOMAS GUERRIER, AURORE COLLET, ALEXIS LARGY, SILVIA SPECA, SOLANGE VIVIER, FABRICE BRAY, MARTIN FIGEAC, ERIC HACHULLA, MYRIAM LABALETTE, FREDERIC LEPRETRE, SHEHERAZADE SEBDA, CHRISTIAN ROLANDO, VINCENT SOBANSKI, SYLVAIN DUBUCQUOI, DAVID LAUNAY
- P.019** **IMPROVEMENT OF LUNG AND SKIN FIBROSIS IN MURIN BLEOMYCIN SSC MODEL BY RUXOLITINIB DOES NOT RELATED TO EFFEROCTOSIS CAPACITY OF MACROPHAGE**
BELLAMRI NESSRINE, LELONG MARIE, LE TALLEC ERWAN, LESCOAT ALAIN, LECUREUR VALERIE
- P.020** **EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY AND FIBROSIS IN SYSTEMIC SCLEROSIS SKIN**
MIRUNA CARNARU, REBECCA FINE, F. PERRY WILSON, IAN ODELL, MONIQUE HINCHCLIFF

PULMONARY - INTERSTITIAL LUNG DISEASE

- P.021** **PREDICTIVE FACTORS OF INTERSTITIAL LUNG DISEASE PROGRESSION IN THE SINGAPORE SYSTEMIC SCLEROSIS COHORT**
MARIA NOVIANI, SEYED EHSAN SAFARI, GIM GEE TENG, WENG GIAP LAW, GRACE YIN LAI CHAN, AMELIA SANTOSA, CASSANDRA HONG, SUE -ANN NG, ANDREA HSIU LING LOW
- P.022** **ANALYSIS OF THE REGISTRY AND SEARCH FOR SOLUTIONS TO THE PROBLEM OF EARLY DIAGNOSIS OF INTERSTITIAL LUNG DISEASES AGAINST THE BACKGROUND OF AUTOIMMUNE DISEASES**
ALEKSEI NIKISHENKOV, SVETLANA NIKISHENKOVA, STANISLAV TERPIGOVRE, TATIANA KABANOVA
- P.023** **THE EFFECTS OF NINTEDANIB ON IMMUNOPHENOTYPES IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE**
YUKO OTA, YUKA OKAZAKI, MASATAKA KUWANA
- P.024** **MRI ULTRA SHORT ECHO-TIME SEQUENCE IN SYSTEMIC SCLEROSIS – INTERSTITIAL LUNG DISEASE ASSESSMENT AND CORRELATIONS WITH PULMONARY FUNCTION TESTS.**
MARTINA ORLANDI, NICHOLAS LANDINI, COSIMO NARDI, SILVIA BELLANDO RANDONE, COSIMO BRUNJ, SERENA GUIDUCCI, STEFANO COLAGRANDE, MARCO MATUCCI-CERINIC

- P.025** **PRELIMINARY REPORT OF PULMONARY COMPLICATIONS IN A COHORT OF COLOMBIAN SSC PATIENTS: A RETROSPECTIVE COHORT STUDY.**
KEVIN MALDONADO, MAYRA ALEJANDRA MURILLO-GÓMEZ, JORGE BRUCE FLOREZ-SUAREZ, MANUELA RUBIO, GERARDO QUINTANA-LÓPEZ
- P.026** **VOLUMETRIC ANALYSIS OF THE 18F-FDG UPTAKE IN THE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS**
MAXIME MORELLE, EMMANUEL LEDOULT, MICHAEL SOUSSAN, DAMIEN HUGLO, ARSENE MEKINIAN, DAVID LAUNAY, CLIO BAILLET
- P.027** **ANTI-TH/TO POSITIVITY IN SYSTEMIC SCLEROSIS: A DESCRIPTIVE ANALYSIS OF CARDIO-PULMONARY INVOLVEMENT AND EVALUATION OF ORGAN DAMAGE AND MORTALITY IN AN ITALIAN MONOCENTRIC COHORT**
LIALA MOSCHETTI, MARIA GRAZIA LAZZARONI, ILARIA CAVAZZANA, FRANCO FRANCESCHINI, PAOLO AIRO'
- P.028** **ACTIVATION STATES OF MACROPHAGES ISOLATED FROM BRONCHOALVEOLAR LAVAGE OF SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE OR WITHOUT**
YEHYA AL-ADWI, TJI-JOONG GAN, JANNEKE BOSMA, MARCEL VAN DER LEIJ, BART-JAN KRÖESEN, ISABELLA ATZENI, WIM TIMENS, HARRY VAN GOOR, ALJA STEL, HANNIE WESTRA, DOUWE MULDER
- P.029** **DOES EARLY TREATMENT WITH IMMUNOSUPPRESSION PREVENT THE OCCURENCE OF ILD IN SSC?**
MADELON VONK, MERLE BOOTSMA, ELS VAN DEN ENDE
- P.030** **HIGH BRONCHOALVEOLAR FLUID NEUTROPHILS INDEPENDENTLY PREDICT 15-YEAR MORTALITY IN SCLERODERMA PATIENTS WITH INTERSTITIAL LUNG DISEASE NAIVE TO IMMUNOSUPPRESSANT**
ENRICO DE LORENZIS, GERLANDO NATALELLO, LUCREZIA VERARDI, PIER GIACOMO CERASUOLO, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO
- P.031** **SCCA-IGM AS A PREDICTOR OF INTERSTITIAL LUNG DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS**
ELISABETTA ZANATTA, ANDREA MARTINI, ANNA CUBERLI, ALESSANDRA BIASIOLO, FRANCESCO BENVENUTI, PATRIZIA PONTISSO, ANDREA DORIA
- P.032** **ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT**
YASEMIN YALCINKAYA, SHIRKHAN AMIKSHIYEV, NUMUNE ALIYEVA, BAHAR ARTIM-ESEN, AHMET GUL, ZULEYHA BINGOL, GULFER OKUMUS, MURAT INANC
- P.033** **THE CLINICAL ASPECTS OF PATIENTS WHIT SSC-ILD IN DIFFERENT PROGNOSIS INTERVALS DEFINED BY DISCRIMINANT ANALYSIS**
OLGA OVSYANNIKOVA, OLGA KONEVA, LIDIYA ANANYEVA, LUDA GARZANOVA, OXANA DESINOVA, MAYYA STAROVOYTOVA, RUSHANA SHAYAHMETOVA
- P.034** **PURE PROGNOSIS OF SSC-ILD PTS DEFINED BY MODIFICATION OF PROGNOSIS INTERVALS**
OLGA OVSYANNIKOVA, OLGA KONEVA, LIDIYA ANANYEVA, LUDMILA GARZANOVA, OXANA DESINOVA, MAYYA STAROVOYTOVA, RUSHANA SHAYAHMETOVA

PULMONARY - INTERSTITIAL LUNG DISEASE

- P.035 MONITORING EARLY DETECTION OF EXPERIMENTAL SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE THROUGH COLLAGEN V IN HUMAN LIQUID BIOPSY**
WALCY ROSOLIA TEODORO, LAIS BRITO, ANA PAULA PEREIRA VELOSA, ZELITA APARECIDA JESUS QUEIROZ, ANTONIO DOS SANTOS FILHO, SÉRGIO CATANOZI, PERSIVAL SAMPAIO-BARROS, VERA LUIZA CAPELOZZI
- P.036 RISK FACTORS FOR LUNG FUNCTION DECLINE IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE IN A LARGE SINGLE CENTER COHORT**
AHMAD RAMAHJI, DAVID ROOFEH, SARA JAAFAR, ALAIN LESCOAT, VIVEK NAGARAJA, SUIYUAN HUANG, DAVID O'DWYER, KEVIN FLAHERTY, ELLA KAZEROONI, DINESH KHANNA
- P.037 CHEMOKINES CCL2 AND CCL17 AS POTENTIAL SERUM BIOMARKERS FOR INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**
IMON SHOUMITRA BARUA, HÅVARD FRETHEIM, HENRIETTE DIDRIKSEN, ØYVIND MIDTVEDT, TORHILD GAREN, MOGENS AALØKKEN, ØYVIND MOLBERG, JOHN BELPERIO, ANNA-MARIA HOFFMAN-VOLD
- P.038 CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE, MORTALITY AND SURVIVAL RATES DURING LONG-TERM FOLLOW-UP IN A SINGLE TERTIARY CENTER.**
 SHIRI KERET, YOLANDA BRAUN-MOSCOVICI, MORDEHAI YIGLA, LUDA GURALNIK, ALEXANDRA BALBIR-GURMAN
- P.039 NINTEDANIB DOSE ADJUSTMENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 2-YEAR DATA FROM SENSIC-ON**
YANNICK ALLANORE, MADELON C VONK, OLIVER DISTLER, ARATA AZUMA, MAUREEN D MAYES, ALEXANDRA JAMES, VERONIKA KOHLBRENNER, MARGARIDA ALVES, DINESH KHANA, KRISTIN B HIGHLAND
- P.040 SIMPLE BIOLOGICAL PARAMETERS AS BIOMARKERS OF SEVERITY AND OUTCOME IN SYSTEMIC SCLEROSIS**
 LITICIA CHIKHOUNE, THIERRY BROUSSEAU, SANDRINE MORELL DUBOIS, MERYEM MAUD FARHAT, HELENE MAILLARD, EMMANUEL LEDOULT, MARC LAMBERT, CECILE YELNIK, SEBASTIEN SANGES, VINCENT SOBANSKI, ERIC HACHULLA, DAVID LAUNAY
- P.041 LUNG ULTRASOUND (LUS) IN THE SEVERITY ASSESSMENT OF INTERSTITIAL LUNG DISEASE (ILD) IN SYSTEMIC SCLEROSIS (SSC-ILD).**
COSIMO BRUNI, LAVINIA MATTOLINI, LORENZO TOFANI, LUNA GARGANI, NICHOLAS LANDINI, NICOLA ROMA, GEMMA LEPRI, MARTINA ORLANDI, SERENA GUIDUCCI, SILVIA BELLANDO-RANDONE, CHIARA ROMEI, YUHA! WANG, MARCO MATUCCI-CERINIC
- P.042 THE CLINICAL PHENOTYPE OF MIXED CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE**
GONCALO BOLETO, ANNA-MARIA HOFFMAN-VOLD, PATRICE CACOUB, MARCO MATUCCI-CERINIC, JOAO EURICO FONSECA, VALERIA RICCIERI, ALAIN LESCOAT, IVAN CASTELLVÍ BARRANCO, PAOLO AIRO, MASA KUWANA, HODA KAVOSI, ADRIEN MIROUSE, ERWAN LE TALLEC, SILJE REISET, MANUEL ANTONIO, JOSE LUIS TANDAIPAN, JÉRÔME AVOUAC, YANNICK ALLANORE
- P.043 ANALYSES OF VALUABLE MARKERS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL ANALYSIS**
HIKARU HIROSE, TOMOAKI HIGUCHI, KAE TAKAGI, AKIKO TOCHIMOTO, MASAYOSHI HARIGAI, YASUSHI KAWAGUCHI
- P.044 PREVALENCE OF ANTI SYNTHETASE ANTIBODIES AMONG SYSTEMIC SCLEROSIS PATIENTS**
WAKAR GARRA, YAIR LEVY
- P.045 A MULTICENTRIC, ONE-YEAR CLINICAL EXPERIENCE ON THE USE OF NINTEDANIB IN SYSTEMIC SCLEROSIS**
MARCO DE PINTO, LUCA MAGNANI, AMELIA SPINELLA, CLAUDIO GALLUZZO, SOFIA TESTONI, GIANLUIGI BAJOCCHI, CHIARA SCELFO, LUCIA DARDANI, CARLO SALVARANI, DILIA GIUGGIOLI
- P.046 NINTEDANIB IN TREATMENT OF PULMONARY FIBROSIS SECONDARY TO CONNECTIVE TISSUE DISEASE: ASST OVEST MILANESE EXPERIENCE**
ANTONELLA LARIA, ALFREDO MARIA LURATI, DANIELA MAZZOCCHI, KATIA ANGELA RE, MARIAGRAZIA MARRAZZA, ELEONORA ZACCARA, DANIELA BOMPANE, LAURA CASTELNOVO, ANTONIO TAMBURELLO, FRANCESCO BINI, PAOLA MARIA FAGGIOLI, ANTONINO MAZZONE
- P.047 THE POTENTIAL MARKERS STUDY OF RESPONSE TO ANTI-B-CELL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH INTERSTITIAL LUNG DISEASE.**
OLGA KONEVA, LIDIA ANANIEVA, LIUDMILA GARZANOVA, OXANA DESINAVA, OLGA OVSYANNIKOVA, MAYYA STAROVAYTOVA
- P.048 THE DYNAMICS STUDY OF PULMONARY FUNCTION AND SKIN CHANGES IN PATIENTS WITH SYSTEMIC SCLEROSIS DURING THERAPY WITH IMMUNOSUPPRESSANTS AND RITUXIMAB**
OLGA KONEVA, LIDIA ANANIEVA, LIUDMILA GARZANOVA, OXANA DESINAVA, OLGA OVSYANNIKOVA, MAYYA STAROVAYTOVAI
- P.049 SURVEY ON TREATMENT PRACTICES IN SUBCLINICAL INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**
SABRINA HOA, MURRAY BARON, MARIE HUDSON
- P.050 MONITORING OF ANTINUCLEAR ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS AFTER LUNG TRANSPLANTATION**
VICTOR BARREALES RODRIGUEZ, ALFREDO GUILLEN-DEL-CASTILLO, PAULA GUBERN PRIETO, CRISTINA BERASTEGUI GARCIA, ADRIÁN ANTÓN VICENTE, JANIRE PERURENA-NIETO, MARIA ROCA HERRERA, EDUARDO CALLEJAS-MORAGA, ISIDRO SANZ PÉREZ, CALUDIA CODINA CLAVAGUER, VINCENT FONOLLOSA-PLÀ, CARMEN PILAR SIMEON AZNAR

PULMONARY - PULMONARY ARTERIAL HYPERTENSION

- P.051 CLINICAL CHARACTERISTICS OF PULMONARY HYPERTENSION IN JAPANESE PATIENTS WITH SCLERODERMA: A SINGLE-CENTER STUDY**
TATSUAKI NAGANAWA, KONOMI ASHIHARA-AKAMITSU, SHUSAKU FUKAYA, HIDEKATA YASUOKA
- P.052 NAILFOLD CAPILLAROSCOPY PARAMETERS CAN PREDICT PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
NATALIYA KLYAUS, MARIA SIMAKOVA, ALEXEY MASLYANSKIY, OLGA MOISEEVA
- P.053 SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER SSC-PH COHORT**
SHIRKHAN AMIKISHIYEV, YASEMIN YALCINKAYA, NUMUNE ALIYEVA, KONUL MAMMADOVA, BAHAR ARTIM ESEN, AHMET GÜL, AHMET KAYA BILGE, GULFER OKUMUS, MURAT INANC
- P.054 OXYGEN TEST DURING RIGHT HEART CATHETERIZATION: ASSISTANCE IN DIFFERENTIAL DIAGNOSIS?**
ALEXANDER VOLKOV, NATALIA YUDKINA, OLGA ALEXEEVA, EKATERINA NIKOLAEVA, ILDAR KURMUKOV
- P.055 PARAMETERS OF THE REVERSIBILITY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH CONNECTIVE TISSUE DISEASES.**
ALEXANDER VOLKOV, NATALIA YUDKINA, EKATERINA NIKOLAEVA
- P.056 MIRNAS IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: MARKERS AND EFFECTORS**
SHELLY TARTAKOVER MATALON, MOR ZAAROR LEVY, MAIA YAMILA KOHON, AVSHALOM SHALOM, ARIEL BERL, OFIR SHIR-AZ, TZIPI HORNLIK-LURIE, LIAT DRUCKER, YAIR LEVY

CARDIAC

- P.057 CONSENSUS ON THE ASSESSMENT OF SYSTEMIC SCLEROSIS-RELATED PRIMARY HEART INVOLVEMENT (SSC-PHI): WSF/HFA GUIDANCE ON SCREENING, DIAGNOSIS, AND FOLLOW-UP ASSESSMENT**
COSIMO BRUNI, MAYA H. BUCH, ALEKSANDRA DJOKOVIC, GIACOMO DE LUCA, RALUCA B. DUMITRU, ALESSANDRO GIOLLO, ILARIA GALETTI, ALEXIA STEELANDT, KOSTANTINOS BRATIS, YOSSRA A. SULIMAN, IVAN MILINKOVIC, ANNA BARITUSSIO, GHADEER HASAN, ANASTASIA XINTHARAKOU, YOHEI ISOMURA, GEORGE MARKOUSIS-MAVROGENIS, SOPHIE MAVROGENI, LUNA GARGANI, ALIDA L.P. CAFORIO, CARSTEN TSCHÖPE, ARSEN RISTIC, SVEN PLEIN, ELIJAH BEHR, YANNICK ALLANORE, MASATAKA KUWANA, CHRISTOPHER P. DENTON, DANIEL E. FURST, DINESH KHANNA, THOMAS KRIEG, RENZO MARCOLONGO
- P.058 IN SYSTEMIC SCLEROSIS TAPSE/SPAP RATIO CAN BE USED IN ADDITION TO THE DETECT ALGORITHM FOR PULMONARY ARTERIAL HYPERTENSION DIAGNOSIS**
AMALIA COLALILLO, MARIA CHIARA GRIMALDI, VALENTINA VAIARELLO, CHIARA PELLICANO, GIORGIA LEODORI, ANTONIETTA GIGANTE, ANTONELLA ROMANIELLO, EDOARDO ROSATO

PATIENT REPORTED OUTCOMES

- P.059 VALIDATION OF KOREAN VERSION OF THE SCLERODERMA HEALTH ASSESSMENT QUESTIONNAIRE (SSC HAQ)**
HYUN MI KWON, EUN HYE PARK, EUN YOUNG AHN, JIN YOUNG MOON, JIN KYUN PARK, EUN BONG LEE
- P.060 PATIENT-REPORTED OUTCOMES USED TO ASSESS DYSPNEA IN CONNECTIVE TISSUE DISEASES, ILD AND PH. A SYSTEMATIC LITERATURE REVIEW OF MEASUREMENT PROPERTIES USING COSMIN GUIDELINES**
JACQUELINE LEMMERS, CHM VAN DEN ENDE, MADELON VONK
- P.061 POSITIVELY IMPACTING PATIENTS WITH SCLERODERMA THROUGH INTERPROFESSIONAL EDUCATION: AN EMERGING APPROACH**
MICHELLE MORGAN, HANNAH BOWEN, LEE SHAPIRO, PATRICIA FENNEL, LINDA MEENAN, JEFFREY BREWER, JESSICA FARRELL
- P.062 A CROSS-SECTIONAL STUDY ON FACTORS ASSOCIATED WITH SLEEP DISTURBANCE IN SYSTEMIC SCLEROSIS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY**
MARIEKE ALEXANDR NEYER, RICHARD S. HENRY, MARIE-EVE CARRIER, LINDA KWAKKENBOS, BROOKE LEVIS, CATHERINE FORTUNÉ, KAREN GOTTESMAN, GENEVIÈVE GUILLOT, AMANDA LAWRIE-JONES, MAUREEN SAUVÉ, JOEP WELLING, SUSAN J. BARTLETT, LAURA K. HUMMERS, VANESSA MALCARNE, LUC MOUTHON, WARREN R. NIELSON, MARIE HUDSON, ANDREA BENEDETTI, BRETT D. THOMBS

QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL DETERMINANT OF DISEASE

- P.063 DETERMINANTS OF DEPRESSION, QUALITY OF LIFE, HEALTH STATUS AND PHYSICAL LIMITATION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
STEFANIE HEYNE, EVA HAUFE, STEFAN BEISSERT, JOCHEN SCHMITT, CLAUDIA GÜNTHER
- P.064 SYMPTOM EXPERIENCE OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS FROM THE PATIENTS' PERSPECTIVE: A QUALITATIVE STUDY**
ALAIN LESCOAT, SUSAN L MURPHY, YEN T CHEN, NADIA VANNI, FRANCESCO DEL GALDO, DAVID CELLA, MAYA H BUCH, DINESH KHANNA
- P.065 THERAPY SATISFACTION AND HEALTH LITERACY ARE KEY FACTORS TO IMPROVE MEDICATION ADHERENCE IN SYSTEMIC SCLEROSIS**
LUDWIG MATRISCH, GABRIELA RIEMEKASTEN
- P.066 CROSS-SECTIONAL STUDY ON FACTORS ASSOCIATED WITH SYMPTOMS OF ANXIETY AMONG PEOPLE WITH SYSTEMIC SCLEROSIS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY**
SABRINA PROVENCHER, RICHARD S. HENRY, BRETT D. THOMBS
- P.067 CROSS-SECTIONAL STUDY ON FACTORS ASSOCIATED WITH SYMPTOMS OF DEPRESSION AMONG PEOPLE WITH SYSTEMIC SCLEROSIS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY**
SABRINA PROVENCHER, RICHARD S. HENRY, BRETT D. THOMBS

QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL DETERMINANT OF DISEASE

- P.068 IS SLEEP A PROBLEM IN SYSTEMIC SCLEROSIS? – A CROSS-SECTIONAL STUDY**
SUSANA P. SILVA, CAROLINA MAZEDA, GISELA EUGÉNIO, ANABELA BARCELOS
- P.069 EVALUATION OF THE HEALTH ECONOMICS OF SYSTEMIC SCLEROSIS IN NEW ZEALAND**
SREE DEEPIKA PADALA, KAMAL SOLANKI, DOUGLAS WHITE
- P.070 EARLY SYSTEMIC SCLEROSIS: MITOCHONDRIA, FATIGUE AND FIBROMYALGIA**
CHARMAINE VAN EEDEN, NAIMA MOHAZAB, DESIREE REDMOND, ARTHUR JONES, ANDREW MASON, JAN WILLEM COHEN TERVAERT, MOHAMMED OSMAN

VASCULAR (INCLUDING RAYNAUD'S AND RENAL INVOLVEMENT)

- P.071 FREQUENCY AND CLINICAL CHARACTERISTICS OF SCLERODERMA RENAL CRISIS FROM TURKEY: MOST PATIENTS DO NOT HAVE A TREATMENT HISTORY OF HIGH DOSE CORTICOSTEROIDS AND ACE INHIBITORS**
NUMJUNE ALIYEVA, YASEMIN YALCINKAYA, SHIRKHAN AMIKISHIYEV, BAHAR ARTIM ESEN, AHMET GÜL, MURAT INANÇ
- P.072 CAPILLAROSCOPIC PATTERNS IN PATIENTS WITH SYSTEMIC SCLEROSIS-POLYMYOSITIS/DERMATOMYOSITIS (SSC-PM/DM) AND SYSTEMIC SCLEROSIS- RHEUMATOID ARTHRITIS(SSC-RA) OVERLAP SYNDROME.**
OXANA DESINOVA, MAYYA STAROVOYTOVA, LIDIYA ANANYEVA
- P.073 SHOULD WE TREAT RAYNAUD'S PHENOMENON WITH ONLY DIGITAL COLOUR CHANGES OR PERSISTENT DISCOLORATION IN-BETWEEN ATTACKS IN PATIENTS WITH SYSTEMIC SCLEROSIS?**
MICHAEL HUGHES, SUIYUAN HUANG, JOHN PAULING, MAYA SABBAGH, DINESH KHANNA
- P.074 UPREGULATION OF PROSTANOID EP2 RECEPTORS AND MEDITATION OF TREPSTINIL ANTI-PROLIFERATIVE EFFECTS IN SCLERODERMA SMOOTH MUSCLE CELLS**
BASHAR KAHALEH, YONGQING WANG
- P.075 THE EFFECT OF SILVER FIBER GLOVES ON RAYNAUD'S PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS: A DOUBLE-BLIND RANDOMIZED CROSS-OVER TRIAL.**
SOPHIE LIEM, EVA HOEKSTRA, FEMKE BONTE-MINEUR, CESAR MAGRO CHECA, ANNE SCHOUFFOER, RENÉE ALLAART, TOM HUIZINGA, SYTSKE ANNE BERGSTRA, JESKA DE VRIES-BOUWSTRA
- P.076 SAFETY AND PERSISTENCE OF MONTHLY INTRAVENOUS ILOPROST IN SYSTEMIC SCLEROSIS**
PATRÍCIA MARTINS, EDUARDO DOURADO, VASCO C ROMÃO, JE FONSECA, CATARINA RESENDE

- P.077 CORRELATION BETWEEN ARTERIAL STIFFNESS AND NAILFOLD CAPILLARY MICROSCOPIC ABNORMALITIES IN SYSTEMIC SCLEROSIS: RESULTS FROM A SINGLE CENTRE CROSS-SECTIONAL STUDY**
CAROLINA MAZEDA, SUSANA P SILVA, RENATA AGUIAR, JOSÉ M BASTOS, ANABELA BARCELOS
- P.078 SCLERODERMA RENAL CRISIS AND PREGNANCY, CASE REPORT AND EUROPEAN CASE COLLECTION**
THIBAUT NAVEAU, THIERRY SCHAEVERBEKE, ESTABILIZ LAZARO, LOIC SENTILHES, SEBASTIEN RUBIN, BENJAMIN CHAIGNE, DAVID LAUNAY, ALESSANDRA DELLA ROSSA, JOHANN MORELLE, VERONICA CODULLO, CECILE CAZORLA, CLAUDIA COBLINLSCHI, MARIE ELISE TRUCHETET
- P.079 COLOR DOPPLER ULTRASONOGRAPHY OF DIGITAL ARTERIES AND DIGITAL ULCERS DEVELOPMENT IN SYSTEMIC SCLEROSIS**
AMALIA COLALILLO, VALENTINA VAIARELLO, CHIARA PELLICANO, GIORGIA LEODORI, ANTONIETTA GIGANTE, EDOARDO ROSATO
- P.080 SIRT1 MODULATES THE SENESCENT PHENOTYPE IN SCLERODERMA ENDOTHELIAL CELLS**
ELLEN N. MODEL, MORGAN M. OMARA, PAMELA J. PALISOC, DINESH KHANNA, PEI-SUEN TSOU

IMAGING

- P.081 CALCINOSIS CUTIS IS ASSOCIATED WITH BONE DEFICITS ASSESSED BY HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY (HR-PQCT) IN PATIENTS WITH SYSTEMIC SCLEROSIS**
VALENZUELA ANTONIA, CHUNG MELODY, KYLA KENT, CATANESE BENJAMIN, FIORENTINO DAVID, CHUNG LORINDA
- P.082 ULTRA-HIGH FREQUENCY ULTRASOUND VERSUS DUROMETRY AND SKIN SCORE FOR CUTANEOUS ASSESSMENT IN SYSTEMIC SCLEROSIS**
MARCO DI BATTISTA, SAVERIO VITALI, SIMONE BARSOTTI, VALENTINA DINI, MARCO ROMANELLI, ALESSANDRA DELLA ROSSA, MARTA MOSCA
- P.083 MOBILE PHONE THERMOGRAPHY MONITORING AS AN AMBULATORY ASSESSMENT TOOL IN RAYNAUD'S PHENOMENON**
GRAHAM DINSDALE, SHANEES NAZEER, JOANNE MANNING, ANDREA MURRAY, ARIANE HERRICK
- P.084 DEVELOPMENT OF AN AUTOMATED DEEP LEARNING SYSTEM FOR DISCRIMINATING BETWEEN 'SYSTEMIC SCLEROSIS' AND 'NORMAL' CAPILLARIES**
PRAVEEN GURUNATH BHARATHI, MICHAEL BERKS, GRAHAM DINSDALE, JOANNE MANNING, SARAH WILKINSON, ANDREA MURRAY, ARIANE HERRICK, CHRIS TAYLOR
- P.085 HYPERSPECTRAL IMAGING IN SYSTEMIC SCLEROSIS-RAYNAUD PHENOMENON**
AKASH GUPTA GUPTA, SHANNON TEAW, ALYSSA WILLIAMS, F. PERRY WILSON, BRANDON SUMPPIO, BAUER SUMPPIO, MONIQUE HINCHCLIFF

IMAGING

- P.086 STANDARDISED NAILFOLD CAPILLAROSCOPY IN CHILDREN WITH RHEUMATIC DISEASES: A WORLDWIDE STUDY**
KARIN MEISENS, MAURIZIO CUTOLO, DIENEKE SCHONENBERG-MEINEMA, IVAN FOELDVARI, MARIA COMASIA LEONE, YORA MOSTMANS, VALERIE BADOT, ROlando CIMAZ, JOKE DEHOORNE, ELLEN DESCHEPPER, TRACY FRECH, JOHANNA HERNANDEZ-ZAPATA, FRANCESCA INGEGNOLI, ARCHANA KHAN, HARTWIG LEHMANN, ASHIMA MAKOL, MIGUEL MESA-NAVAS, MALGORZATA MICHALSKA-JAKUBUS, ULF MULLER-LADNER, LAURA NUNO-NUNO, REBECCA OVERBURY, MISLAV RADIC, DIVYA RAMADOSS, ANGELO RAVELLI, SILVIA ROSINA, CLARA UDAONDO, MERLJIN VAN DEN BERG, ARIANE HERRICK, ALBERTO SULLI, VANESSA SMITH
- P.087 ACCURACY OF B-LINE AND PLEURAL LINE MODIFICATIONS ON LUNG ULTRASOUND FOR INTERSTITIAL LUNG DISEASE DETECTION IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS: PRELIMINARY STUDY**
DAVIDE MOHAMMAD REZA BEIGI, GRETA PELLEGRINO, FRANCESCA ROMANA DI CIOMMO, MICHELE LOCONTE, ILARIA BISCONTI, KATIA STEFANANTONI, GREGORINO PAONE, FABRIZIO CONTI, VALERIA RICCIERI
- P.088 BIOMECHANICAL PROPERTIES OF HEEL-PAD AND METATARSAL HEAD SOFT TISSUE AND FOOT ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS – A CASE CONTROL STUDY**
HADI POORMOGHIM, IMAN MOHSENI, MANDANA POURIAN, ELHAM ANDALIB
- P.089 COMPARISON OF QUANTITATIVE CAPILLAROSCOPIC PARAMETERS ACROSS DIFFERENT AUTOANTIBODY SUBTYPES IN PATIENTS WITH SYSTEMIC SCLEROSIS**
AMJID RASHID, GRAHAM DINSDALE, CALVIN HEAL, JOANNE MANNING, ANDREA MURRAY, ARIANE L HERRICK
- P.090 ULTRASOUND IN SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW FOCUSING ON VALIDATION AND STANDARDIZATION**
TANIA SANTIAGO, EDUARDO SANTOS, BARBARA RUARO, GEMMA LEPRI, LORRAINE GREEN, MARIE WILDOT, SHINJI WATANABE, ALAIN LESCOAT, ROGER HESSELSTRAND, FRANCESCO DEL GALDO, JOHN PAULING, ANNAMARIA IAGNOCCO, JOSE DA SILVA
- P.091 PREDICTION OF PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS USING QUANTITATIVE COMPUTED TOMOGRAPHY INDEXES IN NEURAL NETWORK MODELING**
DUYGU TEMIZ KARADAG, OZGUR CAKIR, SENAR SAN, AYTEN YAZICI, AYSE CEFLE
- P.092 COMPUTED TOMOGRAPHY BASED QUANTITATIVE PARAMETERS CAN BE USED TO MONITOR TREATMENT RESPONSE IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY**
DUYGU TEMIZ KARADAG, OZGUR CAKIR, FATMA TUNCER, AYTEN YAZICI, AYSE CEFLE
- P.093 NAILFOLD CAPILLAROSCOPY IN SSC: INNOCENT BYSTANDER OR PROMISING BIOMARKER FOR NOVEL SEVERE ORGAN INVOLVEMENT/ PROGRESSION?**
AMBER VANHAECKE, MAURIZIO CUTOLO, OLIVER DISTLER, VALERIA RICCIERI, YANNICK ALLANORE, CHRISTOPHER P. DENTON, ERIC HACHULLA, FRANCESCA INGEGNOLI, ELLEN DESCHEPPER, JÉRÔME AVOUAC, SUZANA JORDAN, DAVID LAUNAY, KARIN MEISENS, CARMEN PIZZORNI, ALBERTO SULLI, MASSIMILIANO VASILE, ARIANE L. HERRICK, VANESSA SMITH

MUSCULOSKELETAL SYSTEM & REHABILITATION

- P.094 INFLAMMATORY MYOPATHIES: CLINICAL-IMMUNOLOGICAL SUBTYPES**
OXANA DESINOVA, ANNA KHELKOVSKAIA-SERGEEVA, MAYYA STAROVOYTOVA, LIDIA ANANYEVA, MARIA CHERKASOVA, RUSHANA SHAYAKHMETOVA, OLGA KONEVA
- P.095 ASSOCIATION OF LOW TRABECULAR BONE SCORE WITH C-REACTIVE PROTEIN IN SYSTEMIC SCLEROSIS**
HYUN-SOOK KIM, KYUNG-ANN LEE
- P.096 PAIN INTENSITY AND INTERFERENCE IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY OF 2157 PARTICIPANTS FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT**
YVONNE C. LEE, RINA S. FOX, LINDA KWAKKENBOS, BROOKE LEVIS, MARIE-EVE CARRIER, JOEP WELLING, MAUREEN SAUVÉ, LUC MOUTHON, ANDREA BENEDETTI, SUSAN J. BARTLETT, JOHN VARGA, BRETT D. THOMBS
- P.097 CONSENSUS-BASED RECOMMENDATIONS CONCERNING COMMUNICATION AND EDUCATION FOR PHYSICAL THERAPISTS IN PRIMARY CARE TREATING PATIENTS WITH SYSTEMIC SCLEROSIS**
SOPHIE LIEM, THEA VLIET VLIELAND, CORNELIA VAN DEN ENDE, LETI VAN BODEGOM-VOS, WILFRED PETER, JESKA DE VRIES-BOUWSTRA

GASTROINTESTINAL INVOLVEMENT / NUTRITION

- P.098 THE IMPORTANCE OF BODY-MASS-INDEX IN PREDICTING SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS USING TREE BASED ALGORITHMS – DEVELOPMENT OF A PREDICTION MODEL**
ALEXANDRU GARAIMAN, CARINA MIHAI, RUCSANDRA DOBROTA, COSIMO BRUNI, SUZANA JORDAN, MURIEL ELHAI, ANNA-MARIA HOFFMANN-VOLD, OLIVER DISTLER, MIKE OLIVER BECKER
- P.099 COMPARISON OF LIVER STIFFNESS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PRIMARY BILIARY CIRRHOSIS: A PROSPECTIVE SINGLE-CENTER COHORT STUDY**
VIKTOR KORENDOVYCH, JAN-GERD RADEMACHER, GOLO PETZOLD, SEBASTIAN BREMER, PETER KORSTEN
- P.100 GUT MICROBIOTA IN SYSTEMIC SCLEROSIS: A SYSTEMATIC METAGENOMIC APPROACH**
TZE CHIN TAN, SVEN PETTERSSON, LAKSHMI CHANDRASEKARAN, YING YING KATY LEUNG, ANDREA HSUI LING LOW
- P.101 GASTROINTESTINAL INVOLVEMENT AND HEALTH RELATED QUALITY OF LIFE IN SYSTEMIC SCLEROSIS PATIENTS**
NÁDIA MARCOS, ANA CORDEIRO, ANA CATARINA DUARTE, SANDRA SOUSA, MARIA JOSÉ SANTOS

GASTROINTESTINAL INVOLVEMENT / NUTRITION

- P.102 SURVEY ON DYSPHAGIA USING SIMPLE QUESTIONNAIRE EAT-10 IN PATIENT WITH SYSTEMIC SCLEROSIS.**
TATSUAKI NAGANAWA, AYAKO KUWABARA, NAOKI DOUSODEN, MARIKA SAWADA, NATSUKO WATANABE, MASASHI SUZUKI, AI UMEDA, KONOMI ASHIHARA-AKAMATSU, MEGUMI KURUMIZAWA, DAISUKE HIRANO, TAKAKO HASHIMOTO, JO NISHINO, SYUSAKU FUKAYA, YOUKO INAMATO, SEIKO SHIBATA, OTAKA YOHEI, HIDEKATA YASUOKA
- P.103 ALTERATIONS IN GUT MICROBIAL COMPOSITION ARE ASSOCIATED WITH GASTROINTESTINAL SYMPTOM SEVERITY IN SYSTEMIC SCLEROSIS**
AUDREY NGUYEN, KRISTOFER ANDRÉASSON, VENU LAGSHETTY, ZSUZSANNA MCMAHAN, HEATHER BUKIRI, SUNGEUN MELANIE LEE, JONATHAN JACOBS, ELIZABETH VOLKMAN
- P.104 GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: PATHOGENETIC ROLE OF GUT MICROBIOME, CYTOKINES AND ADIPOKINES**
ERIKA PIGATTO, MAURO GIOVANNI SCHIESARO, MARCO CAPUTO, MARIANNA BEGGIO, PAOLA GALOZZI, FRANCO COZZI, PAOLO SFRISO
- P.105 GUT MICROBIOTA-DERIVED METABOLITES ARE ASSOCIATED WITH SYSTEMIC SCLEROSIS DISEASE ACTIVITY**
MARIUSZ SIKORA, JOANNA GIEBULTOWICZ
- P.106 EXPRESSION OF APOPTOTIC AND PROLIFERATIVE FACTORS IN THE GASTRIC MUCOSA OF PATIENTS WITH SYSTEMIC SCLEROSIS CORRELATES WITH FORM OF THE DISEASE**
KATARINA BORIC, SNEJEZANA MARDESIC, DUSANKA MARTINOVIC KALITERNA, MISLAV RADIC, IVANA TADIN HADJINA, SANDRA ZEKIC TOMAS, DIJANA PERKOVIC, KATARINA VUKOJEVIC, MIRNA SARAGA BABIC
- P.107 CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND GASTRIC ANTRAL VASCULAR ECTASIA (GAVE)**
CLAUDIA CODINA, ALFREDO GUILLÉN-DEL-CASTILLO, EDUARD CALLEJAS-MORAGA, JANIRE PERURENA-PRIETO, MARIA ROCA-HERRERA, ISIDRO SANZ-PÉREZ, VICENT FONOLLOSA-PLA, CARMEN PILAR SIMEÓN-AZNAR
- P.108 BOWEL VASCULOPATHY IN SYSTEMIC SCLEROSIS (SSC): ULTRASOUND (US) EVALUATION AND CORRELATION WITH GASTROINTESTINAL (GI) SYMPTOMS.**
LAURA COMETI, GIULIA BANDINI, ESTERITA ACCOGLI, ANDREA DOMANICO, LORENZO TOFANI, COSIMO BRUNI, SILVIA BELLANDO-RANDONE, GEMMA LEPRÌ, MARTINA ORLANDI, SERENA GUIDUCCI, LUNA GARGANI, KHADIJA EL AOUFY, GABRIELE CIUTI, ALESSIA FABBRI, FRANCESCO CAPPELLI, FEDERICO PERFETTO, MARCO MATUCCI-CERINIC, ALBERTO MOGGHIGNONE
- P.109 A LOW BODY-MASS-INDEX PREDICTS THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS USING TREE BASED ALGORITHMS – DEVELOPMENT OF A PREDICTION MODEL**
ALEXANDRU GARAIMAN, CARINA MIHAI, RUCSANDRA DOBROTA, COSIMO BRUNI, SUZANA JORDAN, MURIEL ELHAI, ANNA-MARIA HOFFMANN-VOLD, OLIVER DISTLER, MIKE OLIVER BECKER

GENDER-RELATED ISSUES

- P.110 PREVALENCE AND CLINICAL ASSOCIATIONS WITH PRIMARY HYPOGONADISM IN MALE SYSTEMIC SCLEROSIS: A PILOT STUDY**
CHINGCHING FOOCHAROEN, SAPOL THEPWIWATJIT, WICHHEN SIRITHANAPHOL, SURANUT CHAROENSIR, AJANE MAHAKKANUKRAUH, SIRAPHOP SUWANNAROJ
- P.111 EVALUATION OF NEUROPSYCHOLOGICAL OUTCOME OF CHILDREN BORN TO WOMEN WITH SSC THROUGH A MULTIDISCIPLINARY QUESTIONNAIRE ADMINISTERED TO THE MOTHERS: RESULTS FROM A MONOCENTRIC COHORT**
LIALA MOSCETTI, LAURA ANDREOLI, ELEONORA PEDRETTI, ALICE BANO, CECILIA NALLI, FRANCESCA CUCCHI, ANGELA TINCANI, FRANCO FRANCESCHINI, JESSICA GALLI, ELISA FAZZI, PAOLO AIRO', MARIA GRAZIA LAZZARONI
- P.112 SEX DIFFERENCES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH SYSTEMIC SCLEROSIS**
ALEXANDER VOLKOV, NATALIA YUDKINA

RECENT ADVANCES IN ESTABLISHED/APPROVED THERAPIES

- P.113 CHANGES OF MUSCULOSKELETAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS DURING RITUXIMAB THERAPY**
LIUDMILA GARZANOVA, LIDIA ANANYEVA, OLGA KONEVA, OLGA OVSYANNIKOVA, OXANA DESINOVA, MAYYA STAROVYOYTOVA, RUSHANA SHAYAKHMETOVA, ANNA KHELKOVSKAYA-SERGEEVA
- P.114 CHANGES OF LUNG FUNCTION AND SKIN FIBROSIS IN SYSTEMIC SCLEROSIS ON RITUXIMAB THERAPY IN COMPARISON WITH IMMUNOSUPPRESSANTS**
LIUDMILA GARZANOVA, LIDIA ANANYEVA, OLGA KONEVA, OLGA OVSYANNIKOVA, OXANA DESINOVA, MAYYA STAROVYOYTOVA, RUSHANA SHAYAKHMETOVA
- P.115 FIVE YEARS FOLLOW-UP OF AN OPEN-LABEL PROSPECTIVE STUDY OF TREATMENT WITH RITUXIMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS**
LIDIA ANANYEVA, OLGA KONEVA, LIUDMILA GARZANOVA, MAYYA STAROVYOYTOVA, OXANA DESINOVA, OLGA OVSYANNIKOVA, RUSHANA SHAYAKHMETOVA
- P.116 STEM CELL MOBILIZATION UNDER REDUCED CYCLOPHOSPHAMIDE DOSING**
ANN-CHRISTIN PECHER, ACH KATHARINA RENATE, HENES JOERG
- P.117 THE COURSE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ANTI-U1RNP ANTIBODIES TREATED WITH RITUXIMAB**
RUSHANA SHAYAKHMETOVA, LIDIA ANANYEVA, OLGA KONEVA, MAYYA STAROVYOYTOVA, OLGA OVSYANNIKOVA, OXSANA DESINOVA, LIUDMILA GARZANOVA, ANNA KHELKOVSKAYA-SERGEEVA, ANASTASIA KOLTAKOVA

RECENT ADVANCES IN ESTABLISHED/APPROVED THERAPIES

- P.118 INTRAVENOUS ILOPROST IN SYSTEMIC SCLEROSIS AND ITS EFFECT IN CARDIOPULMONARY FUNCTION: A RETROSPECTIVE OBSERVATIONAL STUDY**
ROSARIO FOTI, GIORGIO AMATO, ALESSIA BENENATI, YLENIA DAL BOSCO, CATERINA GAGLIANO, ROBERTA FOTI, SALVATORE BELLOFIORE, ELISA VISALLI
- P.119 OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS UNDERGOING EARLY VERSUS DELAYED INTERVENTION WITH POTENTIAL DISEASE-MODIFYING THERAPIES**
KEINA YOMONO, MASATAKA KUWANA

PAEDIATRIC SCLERODERMA

- P.120 PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS HAVE A DISTINCT PATTERN OF ORGAN INVOLVEMENT. RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT.**
IVAN FOELDVARI, JENS KLOTSCH, OZGUR KASAPCOPIR, AMRA ADROVIC, KATHRYN TOROK, MARIA TERESA TERRERI, ANA PAAULA SAKAMOTO, FLAVIO SZTAJNBOK, BRIAN FELDMAN, VALDA STANEVICH, JORDI ANTON, RAJU KHUBCHANDANI, EKATERINA ALEXEEVA, SINDHU JOHNSON, MARIA KATSIKAS, SUJATA SAWHNEY, VANESSA SMITH, SIMONE APPENZELLER, TADEY AVCIN, MIKHAIL KOSTIK, THOMAS LEHMAN, EDOARDO MARRANI, DIENEKE SCHONENBERG-MEINEMA, W-ALBERTO SIFUENTES-GIRALDO, NATALIA VASQUEZ-CANIZARES, NICOLA HELMUS
- P.121 MALE JUVENILE SYSTEMIC SCLEROSIS PATIENTS HAVE MORE SEVERE DISEASE. RESULTS FROM THE INTERNATIONAL JUVENILE SCLERODERMA INCEPTION COHORT**
IVAN FOELDVARI, JENS KLOTSCH, OZGUR KASAPCOPIR, AMRA ADROVIC, KATHRYN TOROK, MARIA TERESA TERRERI, ANA PAAULA SAKAMOTO, FLAVIO SZTAJNBOK, BRIAN FELDMAN, VALDA STANEVICH, JORDI ANTON, RAJU KHUBCHANDANI, EKATERINA ALEXEEVA, SINDHU JOHNSON, MARIA KATSIKAS, SUJATA SAWHNEY, VANESSA SMITH, SIMONE APPENZELLER, TADEY AVCIN, MIKHAIL KOSTIK, THOMAS LEHMAN, EDOARDO MARRANI, DIENEKE SCHONENBERG-MEINEMA, W-ALBERTO SIFUENTES-GIRALDO, NATALIA VASQUEZ-CANIZARES, NICOLA HELMUS
- P.122 JUVENILE SYSTEMIC SCLEROSIS (JSSC) PATIENTS WITH OVERLAP CHARACTERISTICS DO NOT HAVE MILD DISEASE. RESULTS FROM THE JSSC INCEPTION COHORT**
IVAN FOELDVARI, JENS KLOTSCH, OZGUR KASAPCOPIR, AMRA ADROVIC, KATHRYN TOROK, MARIA TERESA TERRERI, ANA PAAULA SAKAMOTO, FLAVIO SZTAJNBOK, BRIAN FELDMAN, VALDA STANEVICH, JORDI ANTON, RAJU KHUBCHANDANI, EKATERINA ALEXEEVA, SINDHU JOHNSON, MARIA KATSIKAS, SUJATA SAWHNEY, VANESSA SMITH, SIMONE APPENZELLER, TADEY AVCIN, MIKHAIL KOSTIK, THOMAS LEHMAN, EDOARDO MARRANI, DIENEKE SCHONENBERG-MEINEMA, W-ALBERTO SIFUENTES-GIRALDO, NATALIA VASQUEZ-CANIZARES, NICOLA HELMUS

- P.123 HOW IS PULMONARY FUNCTION ASSESSED IN JUVENILE SYSTEMIC SCLERODERMA PATIENT? DO WE HAVE A GOOD CLINICAL STANDARD? RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT**
IVAN FOELDVARI, BERND HINRICH, EKATERINA ALEXEEVA, SIMONE APPENZELLER LILLEMOR BERTINSON, JURGEN BRUNNER, PATRICIA COSTA REIS, BRIAN FELDMAN, GERD HORNEFF, MAHESH JANARTHANAN, TILMANN KALLINICH, OZGUR KASAPCOPIR, RAJU KHUBCHANDANI, MIKHAIL KOSTIK, THOMAS LEHMAN, EDOARDO MARRANI, SUSAN NIELSEN, FARZANA NURUZZAMAN, ANJALI PATWARDHAN, MARIA JOSE SANTOS, DIENEKE SCHONENBERG-MEINEMA, VANESSA SMITH, VALDA STANEVICH, FLAVIO SZTAJNBOK, MARIA TERESA TERRERI, KATHRYN TOROK, YOSEF UZIEL, NICOLA HELMUS
- P.124 COMPARATIVE EVALUATION OF JUVENILE-ONSET SYSTEMIC SCLEROSIS AND ADULT-ONSET SYSTEMIC SCLEROSIS**
JENNIFER JY. LEE, BRIAN M. FELDMAN, RONALD M. LAXER, ZAREEN AHMAD, ELVIRA BANGERT, SHAFINA HASMANI, MOHAMMAD MOVAHEDI, SINDHU R. JOHNSON

SCLEROSING SKIN DISEASES (INCLUDING LOCALIZED SCLERODERMA)

- P.125 MOBILE PHONE PHOTOGRAPHY - A POSSIBLE OUTCOME MEASURE OF SYSTEMIC SCLEROSIS-RELATED DIGITAL ULCERS?**
ADRIAN DAVISON, ANDREA MURRAY, GRAHAM DINSDALE, MARK DICKINSON, VICKY TAXIARCHI, ANDY VAIL, HELEN PATRICK, ARIANE HERRICK
- P.126 CO-CREATION OF A TELEMEDICINE GUIDE FOR PATIENTS WITH SYSTEMIC SCLEROSIS**
SUE FARRINGTON, ANN TYRRELL KENNEDY, BEATRIZ GARCIA, CATERINA LEITE, EDITH BROWN, ILARIA GALETTI, MAUREEN SAUVÉ, ROBERT RIGGS, TINA AMPUDIA, LIZETTE MOROS, ANNIE GILBERT
- P.127 SEX DISPARITIES IN CLINICAL CHARACTERISTICS AND LABORATORY TESTS OF CHINESE PATIENTS WITH SYSTEMIC SCLEROSIS**
YUEYING HOU, XINWANG DUAN, QIN LI, HONGBIN LI, JIAXIN ZHOU, YONG HOU, MENGTAO LI, JULIANG ZHAO, QIAN WANG, DONG XU, XIAOFENG ZENG
- P.128 LATE SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT**
MICHAEL HUGHES, SUIYUAN HUANG, JUAN JOSE ALEGRE-SANCHO, PATRICIA E CARREIRA, MERETE ENGELHART, ERIC HACHULLA, JORG HENES, EDUARDO KERZBERG, MARIA ROSA POZZI, GABRIELA RIEMEKASTEN, VANESSA SMITH, GABRIELA SZÜCS, MARIE VANHUYNE, ELISABETTA ZANATTA, OLIVER DISTLER, ARMANDO GABRIELLI, ANNA-MARIA HOFFMANN-VOLD, DINESH KHANNA, EUSTAR COLLABORATORS
- P.129 ECONOMIC BURDEN IN SYSTEMIC SCLEROSIS**
LEONARDO MARTIN CALDERON, MITALI CHAUDHARY, JANET POPE
- P.130 RESOURCE UTILIZATION IN SYSTEMIC SCLEROSIS COMPLICATED BY DIGITAL ULCERS**
LEONARDO MARTIN CALDERON, TATIANA NEVSKAYA, MURRAY BARON, JANET POPE

SCLEROSING SKIN DISEASES (INCLUDING LOCALIZED SCLERODERMA)

- P.131 MORPHO-MECHANICAL PROPERTIES OF MONOCYTES INDICATE DISEASE ACTIVITY, EXTENT OF TISSUE FIBROSIS AND THE RISK FOR FUTURE PROGRESSION IN SYSTEMIC SCLEROSIS**
ALEXANDRU-EMIL MATEI, MARKĚTA KUBÁNKOVÁ, LIYAN XU, ANDREA HERMINA GYÖRFI, EVGENIA BOXBERGER, DESPINA SOTERIOU, MARIA PAPA, JULIA PRATER, XUEZHI HONG, MARTIN KRÁTER, GEORG SCHETT, JOCHEN GUCK, JÖRG H.W. DISTLER
- P.132 SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS**
MICHAEL KREUTER, FRANCESCO BONELLA, KATHRIN KUHR, JOERG JENES, ELISE SIEGERT, GABRIELE RIEMEKASTEN, NORBERT BLANK, CHRISTIANE PFEIFFER, ULF MUELLER-LADNER, ALEXANDER KREUTER, PETER KORSTEN, AARON JUCHE, MARC SCHMALZING, GABRIELE ZEIDLER, MARGITTA WORM, ILONA JANDOVA, LAURA SUSOK, TIM SCHMEISER, CLAUDIA GÜNTHER, GERNOT KEYBER, CORD SUNDERKÖTTER, JAN EHRCHEN, ANDREAS RAMMING, INA KOETTER, HANNS -MARTIN LORENZ, PIA MOINZADEH, NICOLAS HUNZELMANN
- P.133 CHARACTERISTICS OF JAPANESE PATIENTS WITH SYSTEMIC SCLEROSIS COMPLICATED WITH CALCINOSIS**
KAE TAKAGI, HIKARI HIROSE, TOMOAKI HIGUCHI, YASUSHI KAWAGUCHI
- P.134 THE DERMOEPIDERMAL INTERFACE MODULATES COL V FIBRILLOGENESIS IN THE SKIN OF EARLY FIBROSIS IN SYSTEMIC SCLEROSIS**
WALCY ROSOLIA TEÓDORO, ANA PAULA PEREIRA VELOSA, JYMENEZ DE MORAIS, DENISE FREDIANI, SOLANGE CARRASCO, PATRICIA MARTIN, ISABELLE CAMARGO, ZELITA JESUS QUEIROZ, CLÁUDIA GOLDENSTEIN-SCHAINBERG, PERSIVAL SAMPAIO-BARROS, VERA LUIZA CAPELOZZI

EMERGING THERAPIES (INCLUDING PRE-CLINICAL STUDIES)

- P.135 IMMUNOMODULATING ROLE OF THE JAKS INHIBITOR TOFACITINIB IN A MOUSE MODEL OF BLEOMYCIN-INDUCED SCLERODERMA**
WAH WAH AUNG, TAKASHI MATSUSHITA, CHENYANG WANG, JIA XIBEI, MOTOKI HORII, KIE MIZUMAKI, MIYU KANO
- P.136 PHOTOBIO-MODULATION: A NEW LIGHT IN THE TREATMENT OF SYSTEMIC SCLEROSIS SKIN ULCERS**
A SPINELLA, C. GALLUZZO, S. TESTONI, M. DE PINTO, G. AMATI, P MACRIPÒ, F. LUMETTI, L. PARENTI, M. T. MASCIA, C. SALVARANI, D. GIUGGIOLI
- P.137 BLOCKING IL1RAP FUNCTION COUNTERACTS PATHWAYS ASSOCIATED WITH HUMAN SSC AND REDUCES SKIN AND LUNG FIBROSIS IN A MODEL OF SCLERODERMATOUS GVHD MODEL**
CAITRIONA GRÖNBERG, MEIK KUNZ, SARA RATTIK, DAVID LIBERG, JÖRG H.W. DISTLER
- P.138 ELIGIBILITY FOR ANTIFIBROTIC TREATMENT WITH NINTEDANIB OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE**
GERLANDO NATALELLO, ENRICO DE LORENZIS, LUCREZIA VERARDI, PIER GIACOMO CERASUOLO, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO

- P.139 WITHDRAWN**
- P.140 PHASE 1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACE-1334 ON TOP OF STANDARD OF CARE IN SYSTEMIC SCLEROSIS WITH AND WITHOUT INTERSTITIAL LUNG DISEASE**
DINESH KHANNA, CHRISTOPHER DENTON, OLIVER DISTLER, ROBERT LAFYATIS, TOBY MAHER, STEVEN RICHARDS, JIM WAKEFIELD, JOSEPH REYNOLDS

COVID-19-RELATED TOPICS

- P.141 ANALYSIS OF THE FREQUENCY, SEVERITY, AND CONSEQUENCES OF SARS COV2 INFECTION IN PATIENTS WITH SYSTEMIC SCLEROSIS IN REPUBLIC OF MOLDOVA**
SVETLANA AGACHI, LILIANA GROPPA, SERGHEI POPA, LARISA ROTARU, ELENA DESEATNICOVA, LUCIA DUTCA
- P.142 COVID-19 INFECTIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS: FACTORS ASSOCIATED WITH HOSPITALIZATION**
NUMUNE ALIYEVA, YASEMIN YALCINKAYA, SIRKHAAN AMIKISHIYEV, MURAT BEKTAS, BUSRA DEMIR, MELODI GIZEM CAN, RANA GUNOZ COMERT, BAHAR ARTIM ESEN, AHMET GUL, MURAT INANC
- P.143 EVALUATION OF PATIENT-GENERATED DIGITAL IMAGES TO MANAGE DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS DURING COVID-19**
CHENG POU CHAN, GRAHAM DINSDALE, JOANNE MANNING, ELIZABETH WRAGG, ARIANE HERRICK, MUDITHA SAMARANYAKA
- P.144 CORRELATES OF CANCELLED HEALTHCARE APPOINTMENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS DURING THE COVID-19 PANDEMIC**
NANCY DORR, PATRICIA FENNELL, LEE SHAPIRO
- P.145 SCLERODERMA RENAL CRISIS AFTER INFECTION WITH COVID-19**
NOUR EL HOUDA GUÉDICHE, ZEINEB JERBI, NAJAH BOUSSETTA, BILEL ARFAOUI, NADIA BEN ABDELHAFIDH, FAIDA AJILI, SAMAH SAYHI, BASSEM LOUZIR
- P.146 A LONGITUDINAL EXAMINATION OF MENTAL HEALTH PRE- AND DURING COVID-19: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY**
RICHARD HENRY, RICHARD HENRY, LINDA KWAKKENBOS, MARIE -EVE CARRIER, ELALEM NEGERI, ANGELICA BOURGEOULT, SCOTT PATTEN, SUSAN BARTLETT, LUC MOUTHON, JOHN VARGA, ANDREA BENEDETTI, BRETT THOMBS
- P.147 SEVERITY AND MORTALITY OF COVID-19 IN PATIENTS WITH SYSTEMIC SCLEROSIS: A MULTICENTER BRAZILIAN STUDY**
LUCAS MARTINS, SANDRA MAXIMIANO DE OLIVEIRA, ANA PAULA LUPINO-ASSAD, ANA CRISTINA MEDEIROS-RIBEIRO, DANIELA APARECIDA DE MORAES, MARIA CAROLINA DE OLIVEIRA, ANA PAULA TOLEDO DEL-RIO, PERCIVAL DEGRAVA SAMPAIO-BARROS, CRISTIANE KAYSER

COVID-19-RELATED TOPICS

- P.148** **QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS CONFINED BY COVID-19 PANDEMIC IN ARGENTINA**
FABIANA MONTOYA, ALEJANDRO BRIGANTE, GABRIELA SALVATIERRA, MIRTHA SABELLI, GISELA PENDON, FABIAN CARO, JOSEFINA MOLINA, ALEJANDRO NITSCHKE, DEMELZA YUCRA, JULIETA MORBIDUCCI, MARINA DALPIAZ, PAULA PUCCI, MARIA ELENA CRESPO, GABRIELA SANCHEZ, SILVANA CONTI, SANDRA NAVARRO, NATALIA TAMBORENEA
- P.149** **ACCESS TO THE HEALTHCARE SYSTEM IN PATIENTS WITH SYSTEMIC SCLEROSIS DURING THE COVID-19 PANDEMIC IN ARGENTINA**
NATALIA TAMBORENEA, ALEJANDRO BRIGANTE, GABRIELA SALVATIERRA, MIRTHA SABELLI, GISELA PENDON, FABIAN CARO, JOSEFINA MOLINA, ALEJANDRO NITSCHKE, DEMELZA YUCRA, JULIETA MORBIDUCCI, MARINA DALPIAZ, PAULA PUCCI, MARIA ELENA CRESPO, SANDRA NAVARRO, SILVANA CONTI, GABRIELA SANCHEZ, FABIANA MONTOYA
- P.150** **COVID 19 AND SYSTEMIC SCLEROSIS: IMPACT OF THE INFECTION ON A COHORT OF PATIENTS IN SOUTHERN ITALY.**
CATERINA NACLERIO, ANTONIETTA CAVALLERA, GAETANO CICCHITTO, FABIO CRESCIBENE, ANTONIO CAPUOZZO, TERESA URRARO, CAROLINA BENIGNO, FRANCESCO FERRIGNO, ROSITA MARCHITIELLO, GIUSEPPE RESCIGNO, ADELE ROVETTI, GIOVANNA ABATE, SALVATORE SCARPATO
- P.151** **PREVALENCE OF AND RISK FACTORS OF DEATH IN SYSTEMIC SCLEROSIS PATIENTS WITH COVID-19- SINGLE CENTER REPORT.**
HADI POORMOGHIM, FATEMEH GAFFARIRAD, SHAHRZAD RAHMANI, NEGIN MOHTASHAM
- P.152** **SYSTEMIC SCLEROSIS AND COVID-19 – A SINGLE CENTER'S EXPERIENCE**
BEATRIZ SAMOES, DIOGO FONSECA, TIAGO BEIRÃO, FLÁVIO COSTA, ROMANA VIEIRA, TACIANA VEIDEIRA, PATRICIA PINTO, JOANA ABELHA-ALEIXO
- P.153** **FATAL CASES OF COVID-19 IN PATIENTS WITH SYSTEMIC SCLEROSIS: EXPERIENCE OF ONE CENTER**
MAYYA STAROVYOYTOVA, OXANA DESINOVA, [LIDIA ANANYEVA](#), OLGA KONEVA, LUDMILA GARZANOVA, OLGA OVSYANNIKOVA, RUSHANA SHAYAKHMETOVA, VALERIYA BABAK, ANNA HELKOVSKAYA-SERGEEVA
- P.154** **TELEMEDICINE IN SCLERODERMA: IMPACT OF DISEASE ON PATIENT PERCEPTION AND RHEUMATOLOGIST PERSPECTIVE.**
YOSSRA SULIMAN, JULIA MUMPER, CAMERON M HAY, REGINA SATTIEWHITE, ARELIZ LOPEZ, GARY R FELDMAN, DANIEL E FURST
- P.155** **IMPACT OF ILOPROST WITHDRAWAL IN SCLERODERMA PATIENTS DUE TO COVID-19 PANDEMIC**
LUCREZIA VERARDI, ENRICO DE LORENZIS, GERLANDO NATALELLO, LAURA GIGANTE, PIER GIACOMO CERASUOLO, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO
- P.156** **INCIDENCE AND PROGNOSIS OF COVID-19 FIRST-WAVE IN SCLERODERMA PATIENTS IN THE URBAN AREA OF ROME**
ENRICO DE LORENZIS, MIRKO DI MARTINO, MARINA DAVOLI, SALVATORE SOLDATI, GERLANDO NATALELLO, ANDREA BARBARA, LUCREZIA VERARDI, PIER GIACOMO CERASUOLO, MARIA MERLINO, ANTONELLA GEMMA, DONATELLA BILIOTTI, MAURO GOLETTI, VINCENZO BRUZZESE, PAOLO PARENTE, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO

- P.157** **UNDERSTANDING PARTICIPANTS' AND RESEARCH TEAM MEMBERS' EXPERIENCES WITHIN THE SPIN-CHAT PROGRAM TO PROMOTE PSYCHOLOGICAL HEALTH IN THE CONTEXT OF COVID-19**
AMANDA WURZ, DELANEY DUCHEK, MANNAT BANSAL, KELSEY ELLIS, BRETT THOMBS, S. NICOLE CULOS-REED
- P.158** **SARS-COV-2 INFECTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**
HASSELL REBECCA, BIMBA F. HOYER, HANNS -MARTIN LORENZ, ALEXANDER PFEIL, ANNE C. REGIERER, JUTTA G. RICHTER, TIM SCHMEISER, ANJA STRANGFELD, REINHARD E. VOLL, HENDRIK SCHULZE-KOOPS, ANDREAS KRAUSE, CHRISTOF SPECKER, ULF MÜLLER-LADNER

MISCELLANEOUS

- P.159** **INCREASED EXPRESSION OF THEECTOENZYME CD38 IN PERIPHERAL BLOOD PLASMA BLASTS AND PLASMA CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS (SCLERODERMA)**
SILVIA AGARBATI, DEVIS BENFAREMO, NADIA VIOLA, CHIARA PAOLINI, SILVIA SVEGLIATI BARONI, ADA FUNARO, ANDREA COSTANTINI, FABIO MALAVASI, ARMANDO GABRIELLI, GIANLUCA MORONCINI
- P.160** **VITAMIN D LEVELS IN SERUM OF PATIENTS WITH SYSTEMIC SCLEROSIS AND VERY-EARLY SYSTEMIC SCLEROSIS (VEDOSS)**
GIOVANNA CUOMO, MARIA CONSIGLIA TROTTA, STEFANIA PIANESE, CIRO ROMANO, MICHELE D'AMICO
- P.161** **SYSTEMIC SCLEROSIS-SYSTEMIC LUPUS ERYTHEMATOSUS OVERLAP SYNDROME**
OXANA DESINOVA, VALERIYA BABAK, MAYYA STAROVYOYTOVA, RUSHANA SHAYAKHMETOVA, [LIDIA ANANYEVA](#), OLGA KONEVA, LUDMILA GARZANOVA, OLGA OVSYANNIKOVA
- P.162** **CLINICAL AND IMMUNOLOGICAL CHARACTERISATION OF A (VERY) EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS COHORT: CAN AUTOANTIBODIES ADD PROGNOSTIC VALUE?**
EDUARDO DOURADO, RAQUEL FREITAS, PATRÍCIA MARTINS, LILIANA SARAIVA, TÂNIA SANTIAGO, FRANCISCA GUIMARÃES, EMANUEL COSTA, DIOGO ESPERANÇA ALMEIDA, SARA DINIS, ANA SOFIA PINTO, ALEXANDRA DANIEL, MARÍLIA RODRIGUES, MARIA JOÃO SALVADOR, ANA CATARINA DUARTE, ANA CORDEIRO, MARIA JOSÉ SANTOS, JOÃO EURICO FONSECA, INÉS CORDEIRO, CATARINA RESENDE
- P.163** **TOWARDS SYSTEMIC SCLEROSIS REHABILITATION VIA VIDEOGAMES**
MARICA DOVERI, MARCO TROMBINI, ROSSANA GALLI, FEDERICA FERRERO, ANNALaura BARGERI, SIMONE RANDO, SILVANA DELLEPIANE, GEROLAMO BIANCHU
- P.164** **CLINICAL CHARACTERISTICS OF PATIENTS WITH OVERLAP SYNDROMES ASSOCIATED WITH SYSTEMIC SCLEROSIS – RESULTS FROM A SINGLE TERTIARY CARE CENTER**
KRISTÓF FILIPÁNITS, GABRIELLA NAGY, CECÍLIA VARJÚ, ANTONIETTA KOVÁCS, DALMA KOMJÁTI, ZSÓFIA KISNÉ BÁLINT, LÁSZLÓ CZIRJÁK, GÁBOR KUMÁNOVICS, TÜNDE MINIER
- P.165** **THE IMPACT OF THE OVERLAP SYNDROMES ON THE GLOBAL DISEASE ACTIVITY INDICATORS IN SYSTEMIC SCLEROSIS – RESULTS FROM A SINGLE TERTIARY CARE CENTER**
TÜNDE MINIER, KRISTÓF FILIPÁNITS, GABRIELLA NAGY, CECÍLIA VARJÚ, ANTONIETTA KOVÁCS, DALMA KOMJÁTI, ZSÓFIA KISNÉ BÁLINT, LÁSZLÓ CZIRJÁK, GÁBOR KUMÁNOVICS

MISCELLANEOUS

- P.166 EXTENT OF DAMAGE BASED ON THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX- RESULTS FROM A SINGLE TERTIARY EUSTAR CENTER**
TÜNDE MINIER, KRISTÓF FILIPÁNITS, GABRIELLA NAGY, ANTONIETTA KOVÁCS, DALMA KOMJÁTI, ZSÓFIA KISNÉ BÁLINT, GÁBOR KUMÁNOVICS, LÁSZLÓ CZIRJÁK, CECILIA VARJÚ
- P.167 FINGERPRINT COMPARISON BETWEEN BEFORE DISEASE ONSET AND AFTER DIAGNOSIS IN SYSTEMIC SCLEROSIS**
CHINGCHING FOOCHAROEN, WARUT T.SRIWONG, PATTAYARAT SRISANGWARIN, AJANEE MAHAKKANUKRAUH, SIRAPHOP SUWANNAROJ
- P.168 CALCINEURIN INHIBITORS IN SYSTEMIC SCLEROSIS - A SYSTEMATIC LITERATURE REVIEW**
NINA HOFMANN, ROBERT AMBÜHL, SUZANA JORDAN, OLIVER DISTLER
- P.169 CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA : DATA FROM THE INTERNATIONAL EUSTAR DATABASE**
ALAIN LESCOAT, SUIYUAN HUANG, PATRICIA E. CARREIRA, ELISE SIEGERT, JESKA DE VRIES-BOUWSTRA, JÓRG DISTLER, VANESSA SMITH, FRANCESCO DEL GALDO, BRANIMIR ANIC, NEMANJA DAMJANOV, SIMONA REDNIC, CAMILLO RIBI, DOMINIQUE FARGE BANCEL, ANNA -MARIA HOFFMAN-VOLD, ARMANDO GABRIELLI, OLIVER DISTLER, DINESH KHANNA, YANNICK ALLANORE, EUSTAR COLLABORATORS
- P.170 ANALYSIS OF CLINICAL MANIFESTATIONS AT THE DIFFERENT AGE OF ONSET IN SYSTEMIC SCLEROSIS**
SIYAO LIU, YUEYING HOU, JIAXIN ZHOU, YONG HOU, MENGTAO LI, JIULIANG ZHAO, QIAN WANG, DONG XU, XIAOFENG ZENG
- P.171 CANCER IN SYSTEMIC SCLEROSIS PATIENTS**
JOSEFINA MOLINA, BRENDA VARELA, ALEJANDRO NITSCHÉ
- P.172 LOW BODY MASS INDEX IN PATIENTS WITH RAYNAUD PHENOMENON IS ASSOCIATED WITH ENLARGED CAPILLARIES AND REDUCTION IN CAPILLARY DENSITY AT NAILFOLD VIDEOCAPILLAROSCOPY**
GERLANDO NATALELLO, LUCREZIA VERARDI, CATERINA POLICOLA, LAURA GIGANTE, PIER GIACOMO CERASUOLO, FRANCESCA SCARASCIA MUGNOZZA, ENRICO DE LORENZIS, SILVIA DELLA CASA, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO
- P.173 SERUM MAR1 LEVELS IN DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS**
CHIARA PELLICANO, LAURA ROMAGGIOLI, MARZIA MIGLIONICO, AMALIA COLALILLO, ANTONIETTA GIGANTE, EDOARDO ROSATO
- P.174 CH50 ACTIVITY AND C2 LEVELS IN SYSTEMIC SCLEROSIS PATIENTS**
CHIARA PELLICANO, MARZIA MIGLIONICO, LAURA ROMAGGIOLI, AMALIA COLALILLO, LORENZO VANTAGGIO, ANTONIETTA GIGANTE, UMBERTO BASILE, EDOARDO ROSATO
- P.175 MANAGEMENT PITFALLS AND PREVALENCE OF LOST TO FOLLOW-UP DUE TO UNPREDICTED DEATH IN SYSTEMIC SCLEROSIS PATIENTS**
PATNARIN PONGKULKIAT, CHINGCHING FOOCHAROEN, ORATHAI WANTHA, AJANEE MAHAKKANUKRAUH, SIRAPHOP SUWANNAROJ

- P.176 NEGATIVE CHANGES IN NUTRITIONAL STATUS OF SCLERODERMA PATIENTS AND ASSOCIATIONS WITH DISEASE-SPECIFIC FEATURES**
ORESKÁ SABINA, HANA STORKANOVA, MAJA SPIRITOVIC, BARBORA HERMANKOVA, MICHAL VRABLIK, KAREL PAVELKA, JIRI VENCOSKY, LADISLAV SENOLT, RADIM BECVAR, MICHAL TOMCIK
- P.177 ANTI-SSA ANTIBODIES AND DISEASE DURATION ARE COMBINED RISK FACTORS OF CANCER IN SCLERODERMA PATIENTS**
LEA LOPEZ, THOMAS BARNETLICH, THIERRY SCHAEVERBEKE, CHRISTOPHE RICHEZ, MARIE KOSTINE, MARIE-ELISE TRUCHETET
- P.178 CANCER RISK IN IMMUNOSUPPRESSED SCLERODERMA PATIENTS: A PROPENSITY SCORE MATCHING ANALYSIS**
LUCREZIA VERARDI, ENRICO DE LORENZIS, GERLANDO NATALELLO, PIER GIACOMO CERASUOLO, MARIA ANTONIETTA D'AGOSTINO, SILVIA LAURA BOSELLO

CASE REPORTS

- P.179 CASE SERIES: EXTENSIVE CALCINOSIS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS WITH MYOSITIS OVERLAP**
SHELLA ACHIENG, MUDITHA SAMARANAYAKA, ARIANE L HERRICK
- P.180 PARANEOPLASTIC SCLERODERMA SYNDROME REVEALING AN ADENOCARCINOMA OF THE LUNG: A CASE REPORT**
WYSSAL CHAWAD, MOUNA MAAMAR, HAJAR KHBIRI, FATIMA IBOURK IDRISSE, NISSRINE JAÏT, SAFAE FIRDAOUS FARI, ASMAE TAOUCH, SAMI BELKHETTAB, NAÏMA MOUATASSIM, WAFAE AMMOURI, HICHAM HARMOUCHE, ZOUBIDA TAZI, MOHAMMED ADNAOUI
- P.181 WITHDRAWN**
- P.182 DIFFUSE INFLAMMATORY SYSTEMIC SCLEROSIS FOLLOWING SARS-COV-2 VACCINATION**
ALICE COLE, VOON ONG, MANIVANNAN PRATHAP Singh, CHRISTOPHER DENTON
- P.183 A CASE OF PANSCLEROTIC MORPHEA TREATED WITH RITUXIMAB**
 OXANA DESINOVA, MAYYA STAROVOYTOVA, LIDIA ANANYEVA
- P.184 GLOSSOPHARYNGEAL NERVE DEFICIT REVEALING A SYSTEMIC SCLEROSIS SINE SCLERODERMA**
OMAR DHRIF, MHAMDI GHADA, ABDOU GHADA, AOUI NI KARAM, BEJI MAHER
- P.185 POST-COVID PULMONARY HYPERTENSION IN A PATIENT WITH SYSTEMIC SCLEROSIS - RHEUMATOID ARTHRITIS OVERLAP SYNDROME**
DANIL DIBROV, MAYYA STAROVOYTOVA, OXANA DESINOVA
- P.186 OUTCOMES OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AN OVERLAPPING CASE OF SYSTEMIC SCLEROSIS AND IGG4-RELATED DISEASE**
ALISA JULIJA DULKO, RITA RUGIENE, IRENA BUTRMIENE
- P.187 MASSIVE PSEUDOTUMORAL CALCINOSIS IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS: A CASE SERIES**
CLAUDIO GALLUZZO, A. SPINELLA, S. TESTONI, M. DE PINTO, G. AMATI, M.T. MASCIA, C. SALVARANI, D. GIUGGIOLI

CASE REPORTS

- P.188** **PRIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS**
 NOUR EL HOUDA GUEDICHE, NAJAH BOUSSETTA, SAMAH SAYHI, BILEL ARFAOUI, NADIA BEN ABDELHAFIDH, FAIDA AJILI, BASSEM LOUZIR
- P.189** **SCLERODERMA IN CHILDREN WITH PHOTOTYPE VI IN DAKAR, SENEGAL**
 FATIMATA LY, PAPIN TSHAMA TSHIBANGU, BIRAME SECK, MAME TENE NDIAYE, ASTOU DIOUF, FATOU GUEYE DIAGNE, HELENA BOUGAIRE, NDEYE NGOM, ASSANE DIOP, MOUSSA DIALLO
- P.190** **A STONE IN THE SHOE: CALCINOSIS CUTIS AT THE CALCANEUS IN A PATIENT WITH LIMITED SYSTEMIC SCLEROSIS AND DERMATOMYOSITIS OVERLAP SYNDROME**
 MARINA BARGUIL MACEDO, DIOGO SOUZA DOMICIANO, SAMUEL KATSUYUKI SHINJO
- P.191** **COVID-19 PNEUMONIA IN A PATIENT WITH SYSTEMIC SCLEROSIS, ILD AND FIBROELASTOSIS**
 FABIANA MONTOYA, EDUARDO KERZBERG, ANGELES BARTH
- P.192** **TOCILIZUMAB USE IN SYSTEMIC SCLEROSIS PATIENTS WITH CARDIAC INVOLVEMENT: CASE REPORT**
 ZHENG CONG LEE, MARIA NOVIANI, SUE -ANN NG, ANDREA HSIU LING LOW
- P.193** **THE 5 YEARS EXPERIENCE: SUCCESSFUL IMPROVEMENT OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. LONG-TERM EXPERIENCE OF 2 CASES**
 FRANCISCO ORTIZ-SANJUÁN, SAMUEL LEAL RODRIGUEZ, ELENA GRAU GARCÍA, CARMEN RIESCO BÀRCENA, ANDERSON HUAYLLA QUISPE, CRISTÓBAL PÁVEZ PERALES, MARTA DE LA RUBIA NAVARRO, ISABEL MARTINEZ CORDELLAT, LAURA MÀS SÁNCHEZ, PABLO MUÑOZ MARTÍNEZ, CARMEN NÁJERA HERRANZ, ROSA NEGUEROLES ALBUIXECH, JOSE ELOY OLLER RODRIGUEZ, ELVIRA VICENS BERNABEU, CRISTINA ALCAÑIZ ESCANDELL, INÉS CÁNOVAS OLMOS, JORGE FRAGIO GIL, LUIS GONZÁLEZ PUIG, JOSE IVORRA CORTÉS, JOSE A. ROMÁN IVORRA
- P.194** **SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS OVERLAP SYNDROME – MANAGEMENT OF SEVERE CARDIAC, PULMONARY AND ARTICULAR INVOLVEMENT**
 ANA SOFIA PINTO, FILIPE CUNHA SANTOS, SARA PAIVA DINIS, JOANA FONSECA FERREIRA, CLÁUDIA VAZ
- P.195** **A RARE CASE OF TRIGEMINAL NEUROPATHY IN SYSTEMIC SCLEROSIS WITH PM-SCL ANTIBODIES**
 KAMAL SOLANKI, JOANNA SCHOLLUM, DOUGLAS WHITE, CHARLES WERREN, DAVID HARRIS
- P.196** **THE DEVELOPMENT OF SEVERE NOVEL CORONAVIRUS PNEUMONIA IN A PATIENT WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AFTER RITUXIMAB THERAPY**
 MAYYA STAROVYOYTOVA, OXANA DESINOVA, PAVEL OVCHAROV, LIDIA ANANYEVA

PATRONAGE

We thank for the patronage and award for the best Italian abstracts



Società Italiana
di Reumatologia

ACKNOWLEDGEMENT

The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

PLATINUM SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



OTHER



Organizing Secretariat



AIM Group International

Florence Office

Viale G. Mazzini, 70

50132 Florence, Italy

ph. +39 055 233881

fax +39 055 2480246

ssc2022@aimgroup.eu

www.worldsclerofound.org